<SEC-DOCUMENT>0001121404-25-000013.txt : 20250424
<SEC-HEADER>0001121404-25-000013.hdr.sgml : 20250424
<ACCEPTANCE-DATETIME>20250424101332
ACCESSION NUMBER:		0001121404-25-000013
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250424
DATE AS OF CHANGE:		20250424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		25864947

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a6kcoverpagepressreleaseq1.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i1e914af250b04f2e8a9b854725229d31_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;6-K</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE&#160;13a-16&#160;OR&#160;15d-16</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the month of April 2025</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number&#58;&#160;001-31368</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANOFI</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Translation of registrant&#8217;s name into English)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">46, avenue de la Grande Arm&#233;e, 75017 Paris, FRANCE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices)</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F&#160;or Form&#160;40-F.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 20-F&#160;&#160;&#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form&#160;40-F&#160;&#160;&#9744;</font></div><div style="margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2025, Sanofi issued the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:18.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit No.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Press release dated April 24, 2025&#58; Sanofi&#58; strong Q1 performance and 2025 guidance confirmed</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.635%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; April 24, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SANOFI</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#47;s&#47; Alexandra Roger</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexandra Roger</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Head of Legal Corporate &#38; Finance</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressreleaseq12025english.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i14830fdb600a46e3afa7ced50445a7af_1"></div><div style="min-height:53.86pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.056%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.592%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Press Release</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:53.86pt;text-align:right"><img alt="fsridynmyoja6nwywy2m1otazoa.gif" src="fsridynmyoja6nwywy2m1otazoa.gif" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:165px"></div></td></tr></table></div></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;margin-top:9pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Sanofi&#58; strong Q1 performance and 2025 guidance confirmed</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Paris, April 24, 2025</font></div><div style="margin-bottom:1pt;margin-top:8pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Q1 sales growth of 9.7% at CER</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> and business EPS</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> of &#8364;1.79</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Pharma launches reached sales of &#8364;0.8 billion, up 43.8%, driven by ALTUVIIIO</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Dupixent sales were &#8364;3.5 billion, up 20.3%</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Vaccines sales were &#8364;1.3 billion, up 11.4%, driven by favorable Beyfortus phasing</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Research and Development expenses reached &#8364;1.8 billion, up 6.9%</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Selling, general and administrative expenses were &#8364;2.2 billion, up 3.8%</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Business EPS was &#8364;1.79, up 15.7% at CER and up 17.0% reported&#59; IFRS EPS was &#8364;1.52</font></div><div style="margin-bottom:1pt;margin-top:8pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pipeline continued to deliver</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Six regulatory approvals across medicines in immunology, rare diseases, and oncology</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Recent new data from the mid-stage pipeline unlocks late-stage studies in asthma and skin diseases, broadening and deepening the scope in immunology</font></div><div style="margin-bottom:1pt;margin-top:8pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sustainability strategy</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Updated sustainability strategy focuses on access to healthcare, environmental impact, and resilience of healthcare systems. 70% of the portfolio and &#62;75% of the pipeline target diseases that are impacted by climate and environmental challenges</font></div><div style="margin-bottom:1pt;margin-top:8pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Capital allocation</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">The closing of the sale of a controlling stake in Opella to CD&#38;R is anticipated in Q2</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">3</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">4</font></div><div style="margin-bottom:1pt;margin-top:8pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Guidance confirmed</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">6</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:line-through">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Sanofi intends to complete a share buyback program in 2025 of &#8364;5 billion of which 72% was already repurchased</font></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Paul Hudson, Chief Executive Officer&#58;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.8pt;font-style:italic;font-weight:400;line-height:120%">&#8220;We had a strong start in 2025 with sales growth of 9.7%, benefiting from investments in innovation and a favorable base of comparison. Our focus on pipeline value delivered further growth for Sanofi with sales from launches of new medicines and vaccines growing by 46.5%. We obtained approval for Qfitlia (fitusiran), a new treatment for patients with hemophilia, one of three potential launches this year. ALTUVIIIO is continuing to gain market share and is on track to become our next blockbuster in the full year. Business EPS was &#8364;1.79, confirming the expected strong rebound in 2025.</font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.8pt;font-style:italic;font-weight:400;line-height:120%">Our redeployment of capital continued with significant progress on our share buyback program, the upcoming closing of the sale of a majority stake in Opella and the recent acquisition of a bispecific myeloid cell engager for deep B-cell depletion in immunology, strengthening our early pipeline and providing a potential treatment option in difficult-to-treat diseases like lupus.</font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.8pt;font-style:italic;font-weight:400;line-height:120%">We achieved significant advances in the pipeline with six approvals. We also delivered steady progress across many new medicines in respiratory diseases and dermatology, including clinically meaningful efficacy for amlitelimab in asthma, allowing us to enter phase 3 development to create future value for patients, society, and our company. Underpinned by the growth in sales and business EPS, we confirm our 2025 guidance with the knowledge of the external environment we have today.&#8221;</font></div><div id="i14830fdb600a46e3afa7ced50445a7af_4"></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:24.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.554%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IFRS net sales reported</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;9,895&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">m</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.8&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+9.7&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IFRS net income reported</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;1,872&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">m</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+65.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IFRS EPS reported</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;1.52&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+67.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Free cash flow<font style="font-size:4.55pt;position:relative;top:-2.44pt;vertical-align:baseline">7</font></font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;1,029&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">m</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Business operating income</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;2,902&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">m</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+18.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Business net income</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;2,212&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">m</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+15.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+14.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Business EPS</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;1.79&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+17.0&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+15.7&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Changes in net sales are at constant exchange rates (CER) unless stated otherwise (definition in Appendix 9).</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> To facilitate an understanding of operational performance, Sanofi comments on the business net income, a non-IFRS financial measure (definition in </font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Appendix 9). The income statement is in Appendix 3 and a reconciliation of net income as reported under IFRS to business net income is in Appendix 4.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Subject to finalization of definitive agreements.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Subject to closing conditions, including receipt of regulatory approvals.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> In 2025, sales growth will exclude any impact from hyperinflation. In FY 2024, it is estimated that sales growth benefited by 1.8 percentage points.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Applying average April 2025 exchange rates, the currency impacts are estimated between -1% and -2% on sales and -1.5% and -2.5% on business EPS.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">7</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Free cash flow is a non-IFRS financial measure (definition in Appendix 9).</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_7"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:9pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Q1 2025 summary</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A conference call and webcast for investors and analysts will begin at 13&#58;00 CEST. Details can be accessed via sanofi.com, including presentation slides.</font></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.332%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">The performance shown in this press release covers the three-month period to March 31, 2025 (the quarter or Q1 2025) compared to the three-month period to March 31, 2024 (Q1 2024). All percentage changes in sales in this press release are at CER.</font></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.332%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Q1 2025, sales were &#8364;9,895 million and increased by 9.7%. Exchange rate movements had a positive effect of 1.1&#160;percentage points (pp)&#59; therefore, as reported, sales increased by 10.8%. The divestments of medicines&#47;portfolio streamlining had a negative impact of 0.4pp on sales growth.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sales by geography</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:49.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.554%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,657&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+15.4&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Europe</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,043&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rest of World</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,195&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+8.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which China</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">701&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.7&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:115%">US</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">sales were &#8364;4,657 million and increased by 15.4%. The performance was driven by pharma launches, Dupixent, and Lantus while legacy medicines were lower. Vaccines sales were broadly stable, including lower sales of Beyfortus.</font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Europe</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;2,043 million and increased by 0.5%. Growth was driven by Dupixent, pharma launches, and Beyfortus. Other main medicines as well as other vaccines outside Beyfortus and Influenza vaccines all experienced lower sales during Q1.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Rest of World</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">sales were &#8364;3,195 million and increased by 8.4%. The performance was led by Dupixent, Beyfortus, pharma launches, insulins, and PPH and booster vaccines while other medicines and flu vaccines declined. </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">China</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;701 million and decreased by 1.7%, generally impacted by the renewed national reimbursement drug list and volume-based procurement.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business operating income</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Q1 2025, business operating income (BOI) was &#8364;2,902 million and increased by 18.7% (20.1% reported) from &#8364;2,417 million in Q1 2024. The ratio of BOI to net sales was 29.3% and increased by 2.2pp (29.3% reported, up by 2.2pp). This increase was mainly driven by a higher gross margin and lower growth in operating expenses.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business development</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business development, including strategic investments in external innovation is an integral part of Sanofi&#8217;s efforts to continuously access optionality for new and promising scientific developments and platforms and replenish the pipeline.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager that has shown robust B-cell depletion in pre-clinical and early clinical studies. DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted phagocytosis. Recent early clinical study data in autoimmune diseases suggest that deep B-cell depletion might have the potential to reset the adaptive immune system, leading to sustained treatment-free remission in patients with refractory B-cell mediated autoimmune diseases such as lupus, where significant unmet medical needs remain.</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">1</font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Subject to closing conditions, including receipt of regulatory approvals.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_10"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:9pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Biopharma segment</font></div><div id="i14830fdb600a46e3afa7ced50445a7af_13"></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharma</font></div><div id="i14830fdb600a46e3afa7ced50445a7af_16"></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Launches</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:49.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.554%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales </font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALTUVIIIO</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">251&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+100.0&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nexviazyme&#47;Nexviadyme</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+26.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sarclisa</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+26.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:133%">Rezurock</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">131&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+36.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:133%">Cablivi</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+11.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Xenpozyme</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+60.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:133%">Tzield</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:133%">Qfitlia</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">847</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+43.8</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">ALTUVIIIO</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (hemophilia A) sales were &#8364;251 million of which 87% were in the US. Growth was driven by continued patient switches from older plasma-derived and recombinant factor medicines and to a lesser extent from non-factor treatments. Rest of World sales of &#8364;33 million benefited from the launch in Japan and sales to the collaborator in Europe. The hemophilia A franchise (ALTUVIIIO and Eloctate combined) sales were &#8364;321 million and increased by 50.0% as Eloctate sustained significant sales levels.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Nexviazyme&#47;Nexviadyme</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (Pompe disease) sales were &#8364;195 million and increased by 26.3%, driven by Europe (+48.8%) and Rest of World (+33.3%). In the US (+12.9%), most eligible patients have converted from Myozyme&#47;Lumizyme. The Pompe disease franchise (Nexviazyme&#47;Nexviadyme and Myozyme&#47;Lumizyme combined) sales were &#8364;330 million and decreased by 5.0% in total.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Sarclisa</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (multiple myeloma) sales were &#8364;136 million and increased by 26.4%, driven by market share gains globally, increased use in earlier lines of treatment, mainly in the second-line setting, but gradually also in front-line combination use.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Rezurock</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (chronic graft-versus-host disease) sales were &#8364;131 million and increased by 36.6%, driven by the US (+31.0%) from solid volume growth and by launches gaining momentum in Europe (sales of &#8364;9 million) and in Rest of World (sales of &#8364;9 million).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Cablivi</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (acquired thrombotic thrombocytopenic purpura) sales were &#8364;67 million and increased by 11.9%, driven by more patients being identified for treatment, aided by using artificial intelligence in the US and from launches in Europe and Rest of World.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Xenpozyme</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (acid sphingomyelinase deficiency) sales were &#8364;56 million and increased by 60.0%, driven by more patients being identified for treatment across all geographies.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Tzield</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (delay onset of type 1 diabetes) sales were &#8364;11 million and increased by 10.0%. After a softer start to the year, sales are anticipated to benefit from the continued investment in increased awareness and improved screening.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Qfitlia</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (hemophilia A and B) was approved in the US on March 28, 2025, with first sales recorded at the beginning of Q2 2025.</font></div><div id="i14830fdb600a46e3afa7ced50445a7af_19"></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Immunology</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:49.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.554%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales </font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dupixent</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,480&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20.3&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Dupixent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;3,480 million and increased by 20.3%. Global sales were driven by increased use in all approved indications, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, and emerging use in COPD. Country launches have commenced in COPD with increased momentum expected during the year. In the US, sales were &#8364;2,476 million and increased by 18.4%. Growth in the US reflected the customary Q1 impact from the annual reset of insurance deductibles leading to higher utilization of the co-pay assistance program. In Europe, Dupixent sales were &#8364;459 million and increased by 23.5% reflecting strong momentum in all approved indications. In Rest of World, sales were &#8364;545 million and increased by 26.5%, driven by Japan.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">3</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_22"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Other main medicines</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:49.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.554%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales </font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lantus</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">450&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+24.4&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Toujeo</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">354&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:133%">Fabrazyme</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">262&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plavix</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lovenox</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">238&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-6.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:133%">Cerezyme</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-9.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:133%">Alprolix</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:133%">Myozyme&#47;Lumizyme</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">135&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-29.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Praluent</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+6.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thymoglobulin</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cerdelga</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Eloctate</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-20.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aubagio</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-37.3&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Lantus</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;450 million and increased by 24.4%. US sales were &#8364;196 million and increased by 68.8% from a lower base in Q1 2024 due to gross-to-net adjustments. Lantus continued to benefit from windfall sales in the US due to the unavailability of a competing medicine. In 2025, customer demand is still expected to normalize depending on windfall sales. In Europe and Rest of World, combined sales increased by 4.4%.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Toujeo</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;354 million and increased by 10.0%, driven by Rest of World (+14.4%) where Toujeo continued to increase its basal insulin market share. Europe sales were broadly stable (+2.5%) while US sales increased (+14.3%).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Fabrazyme</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;262 million and increased by 2.4%, mainly driven by slight growth in the number of patients.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Plavix</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;244 million and increased by 2.5%, reflecting volume growth in Rest of World.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Lovenox</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">sales were &#8364;238 million and decreased by 6.5%, mainly as the result of impact from biosimilar competition in Europe.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Cerezyme</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">sales were &#8364;190 million and decreased by 9.3%, driven by an element of phasing as well as some patients stopping treatment. The Gaucher disease franchise (Cerezyme and Cerdelga) sales were &#8364;276 million and decreased by 6.1%.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Alprolix</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;160 million and increased by 20.0%, benefiting from an increase in US market share and supply sales.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Myozyme&#47;Lumizyme</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;135 million and decreased by 29.8% due to the ongoing shift to Nexviazyme&#47;Nexviadyme.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Praluent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;130 million and increased by 6.6% because of higher sales in Europe, but lower sales in Rest of World.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Thymoglobulin</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;122 million and increased by 2.6%, mainly reflecting increased sales in Rest of World.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Cerdelga</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;86 million and increased by 2.4%, reflecting higher sales in Europe, but lower sales in the US.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Eloctate</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;70 million and decreased by 20.9% because of patients converting to ALTUVIIIO in the US and in Japan.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Aubagio</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">sales were &#8364;65 million and decreased by 37.3%, reflecting losses of exclusivity in the US and the EU in 2023. Aubagio sales are expected to continue to decrease.</font></div><div id="i14830fdb600a46e3afa7ced50445a7af_25"></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vaccines</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:49.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.554%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales </font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV (Beyfortus)</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">284&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+54.9&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Polio&#47;Pertussis&#47;Hib primary and booster vaccines</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">668&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Influenza vaccines</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Meningitis, Travel and endemic vaccines </font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">302&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,326</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+11.4</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Vaccines</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;1,326 million and increased by 11.4%, driven by favorable Beyfortus phasing and geographical roll-out.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Beyfortus</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;284 million, driven by additional sales in the Northern Hemisphere, in particular Germany and Japan. In the US, the immunization rate in Q1 reduced compared to Q4 2024&#59; consequently, an element of the doses sold for the 2024&#47;2025 season may be utilized for immunizations in later quarters. In Rest of World, sales were driven by the roll-out in Japan and Australia. Beyfortus is routinely protecting babies in around 25 countries.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Polio&#47;Pertussis&#47;Hib (PPH) primary and booster vaccines</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;668 million and increased by 3.8%, primarily driven by demand for boosters to re-vaccinate adolescents and adults.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Influenza vaccines</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;73 million and decreased by 1.4%, partly from a higher base of comparison last year in Southern Hemisphere countries, offset by late Northern Hemisphere sales.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Meningitis, Travel and endemic vaccines</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;302 million and increased by 3.5%, reflecting favorable ordering pattern for meningitis in the US, partly offset by phasing of travel and endemic vaccines.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_28"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business operating income</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Q1 2025, Biopharma BOI was &#8364;2,893 million and increased by 19.3% (20.6% reported) from &#8364;2,399 million in Q1 2024. The ratio of BOI to net sales was 29.2% and increased by 2.3pp (29.2% reported, up by 2.3pp). This increase was mainly driven by a higher gross margin and lower growth in operating expenses.</font></div><div id="i14830fdb600a46e3afa7ced50445a7af_31"></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pipeline update</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has 86 projects in a pipeline across four main disease areas (Immunology, Rare diseases, Neurology, and Oncology) and Vaccines, including 41 potential new medicines (NMEs) and vaccines (NVEs). The following section highlights significant developments in the late- and mid-stage pipeline in the quarter.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Highlights</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:31.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.389%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Regulatory approvals</font></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dupixent &#8211; COPD (JP)<br>Qfitlia &#8211; hemophilia A&#47;B (US)<br>Sarclisa &#8211; NDMM (JP)<br>Sarclisa &#8211; NDMM, TI (EU, CN)<br>Sarclisa &#8211; R&#47;R MM (CN)</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Regulatory submission acceptances</font></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dupixent &#8211; BP (US priority review, EU, CN)<br>tolebrutinib &#8211; nrSPMS (US priority review, EU)</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Phase 3 study start</font></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">itepekimab &#8211; CRSwNP</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Immunology</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dupixent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (dupilumab)</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">The Ministry of Health, Labour and Welfare (MHLW) in Japan granted marketing and manufacturing authorization for Dupixent for the treatment of </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">chronic</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">obstructive</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">pulmonary</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">disease</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (COPD) in adults whose disease is not adequately controlled with existing therapy. The approval in Japan was based on data from the BOREAS phase 3 study. In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis, and chronic spontaneous urticaria (CSU). Dupixent for the treatment of COPD has been approved in more than 45 countries worldwide, including the 27 member countries of the EU.</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">The US Food and Drug Administration (FDA) accepted for priority review the supplemental biologics license application (BLA) for Dupixent to treat adults with </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">bullous</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">pemphigoid</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (BP). BP is a chronic, debilitating, and relapsing skin disease with underlying type-2 inflammation that typically occurs in an elderly population. It is characterized by intense itch and blisters, reddening of the skin, and painful lesions. The blisters and rash can form over much of the body and cause the skin to bleed and crust, resulting in patients being more prone to infection and affecting their daily functioning. The target action date for the FDA decision is June 20, 2025. Regulatory applications were also submitted and accepted for review in the EU and China.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">itepekimab</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (IL33 mAb)</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">The CEREN 1 (clinical study identifier&#58; NCT06834347) and CEREN 2 (clinical study identifier&#58; NCT06834360) phase 3 studies of two dose regimens of itepekimab compared with placebo as add-on therapy to intranasal corticosteroids in patients with inadequately controlled </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">CRSwNP</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> commenced dosing the first patient.</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">A proof-of-concept phase 2 study (clinical study identifier&#58; NCT06691113) of two dose regimens of itepekimab compared with placebo in patients with inadequately controlled </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">chronic</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">rhinosinusitis</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">without</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">nasal</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">polyps</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> commenced dosing the first patient.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">amlitelimab</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (OX40L mAb)</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Preliminary results from the TIDE-Asthma phase 2 study (clinical study identifier&#58; NCT05421598) in patients with moderate-to-severe </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">asthma</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> showed that amlitelimab achieved clinically meaningful and durable efficacy on exacerbations, lung function, and symptoms, particularly in heterogeneous inflammation. However, the primary endpoint of exacerbations at high dose did not reach statistical significance due to the nature of this limited phase 2 study. As a result, subsequent endpoints are exploratory. In certain subgroups, including patients with high eosinophils and elevated neutrophils, the reduction in exacerbation reached more than 70%. Amlitelimab was generally well tolerated with no new safety concerns identified. Full results will be presented at a forthcoming medical meeting.</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">The COAST 1 (clinical study identifier&#58; NCT06130566) and SHORE (clinical study identifier&#58; NCT06224348) phase 3 studies, part of the OCEANA study program in </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">AD</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> have completed patient recruitment ahead of schedule. The recruitment of patients proceeded efficiently, providing the opportunity to optimize the overall sample sizes and robustness of the studies. The OCEANA program is anticipated to read out in 2026 and will provide the foundation for potential regulatory submissions.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">duvakitug</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (TL1A mAb)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and Teva presented new, detailed results from the RELIEVE UCCD phase 2b study (clinical study identifier&#58; NCT05499130) of duvakitug at the 20th Congress of the European Crohn&#8217;s and Colitis Organisation in Berlin, Germany in February. Duvakitug is a human IgG1-&#955;2 monoclonal antibody targeting TL1A and was assessed in patients with moderate-to-severe </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ulcerative</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">colitis</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (UC) and </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Crohn&#8217;s</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">disease</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (CD), the two most common forms of inflammatory bowel disease (IBD). In the UC cohort of the RELIEVE UCCD study, 36% (450 mg dose) and 48% (900 mg dose) of patients treated with duvakitug achieved the primary endpoint of clinical remission at week 14 compared to 20% treated with placebo&#59; placebo-adjusted rates were 16% (450 mg dose) and 27% (900 mg dose) (p&#61;0.050 and 0.003, respectively). In the CD cohort of the RELIEVE UCCD study, 26% (450 mg dose) and 48% (900 mg dose) of patients treated with duvakitug achieved the primary endpoint of endoscopic response compared to 13% on placebo&#59; placebo-adjusted rates were 13% (450 mg dose) and 35% (900 mg dose) at </font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">week 14 (p&#61;0.058 and &#60;0.001, respectively). In both the UC and CD cohorts, duvakitug was generally well tolerated with no emergent safety signals observed. A phase 3 program is anticipated to start in H2 2025.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">lunsekimig </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(IL13xTSLP NANOBODY</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> VHH)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A phase 2 study (clinical study identifier&#58; NCT06790121) of three subcutaneous dose regimens of lunsekimig compared with matching placebos in adults with moderate-to-severe </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">AD</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> with a history of an inadequate response to topical treatments or for whom topical therapies are not advised commenced dosing the first patient.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">brivekimig </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(TNFxOX4OL NANOBODY</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> VHH)</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Preliminary results from the HS OBTAIN phase 2 study (clinical study identifier&#58; NCT05849922) in patients with </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">hidradenitis</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">suppurativa</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (HS) na&#239;ve to biologics showed that brivekimig achieved its primary objective</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and showed clinically meaningful improvements in HiSCR50 and other endpoints. The safety profile was in line with expectations with no new safety concerns identified in the 28-week treatment period. Brivekimig, combining dual tumor necrosis factor alpha and OX40 ligand (OX40L) inhibition will be prioritized for further development in HS as OX40L monotherapy (amlitelimab) did not show comparable efficacy in the HS phase 2 study (clinical study identifier&#58; NCT06118099). Full results will be presented at a forthcoming medical meeting.</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">The T1D OBTAIN phase 2 study (clinical study identifier&#58; NCT06812988) of brivekimig compared with placebo to preserve &#946;-cell function in adults (part A) and adolescents (part B) recently diagnosed with </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">type</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">diabetes</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and on insulin therapy commenced dosing the first patient.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">balinatunfib</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (oral TNFR1si)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Preliminary results from the SPECIFIC-PSO phase 2 study (clinical study identifier&#58; NCT06073119 ) in patients with </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">psoriasis</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> showed that balinatunfib was generally well tolerated across doses with no new safety concerns and the potential for differentiated safety. Further, balinatunfib achieved clinically relevant PASI-75 responses, with efficacy levels comparable to other oral medicines in psoriasis. However, the primary endpoint of PASI-75 did not reach statistical significance due to the nature of this limited phase 2 study. As a result, subsequent endpoints are exploratory. With the results obtained, balinatunfib could be well suited for combinations and internal assessments and external discussions are ongoing on potential combinations, including fixed-dose combinations in various diseases. Full results will be presented at a forthcoming medical meeting.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Rare diseases</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Qfitlia </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(fitusiran)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The FDA approved Qfitlia, the first antithrombin (AT)-lowering medicine for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (aged 12 or older) with </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">hemophilia</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">A</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">or</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">B</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> with or without factor VIII or IX inhibitors. The approval was based on data from the ATLAS phase 3 studies that demonstrated clinically meaningful bleed protection as measured by annualized bleeding rates across hemophilia patients with or without inhibitors. In conjunction with the Qfitlia approval, the FDA also cleared Siemens Healthineers&#8217; INNOVANCE&#174; Antithrombin assay as a companion diagnostic for Qfitlia to measure AT levels. The medicine is also under regulatory review in China.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">rilzabrutinib </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(BTK inhibitor)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The FDA granted orphan drug designation to rilzabrutinib for two rare diseases, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">warm</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">autoimmune</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">hemolytic</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">anemia</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (wAIHA) and </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">IgG4-related</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">disease</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (IgG4-RD). There is still a significant unmet medical need for these two rare diseases, and neither have any currently approved medicine. FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Affecting one to three people out of 100,000 in the US each year, wAIHA is a rare, potentially life-threatening, autoimmune disorder where autoantibodies lead to the premature destruction of the body&#8217;s own red blood cells (hemolysis).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IgG4-RD affects approximately eight out of 100,000 adult patients in the US each year and is a rare, progressive, relapsing, chronic fibro-inflammatory condition which can manifest in almost every organ and can lead to organ damage and irreversible dysfunction with a sometimes-fatal outcome.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">frexalimab</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (CD40L mAb) &#47; </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">rilzabrutinib</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (BTK inhibitor) &#47; </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">brivekimig</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (TNFaxOX40L NANOBODY</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> VHH)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The RESULT phase 2 study (clinical study identifier&#58; NCT06500702) of frexalimab, rilzabrutinib, and brivekimig compared with matching placebos in adults with </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">primary</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">focal</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">segmental</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">glomerulosclerosis</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">minimal</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">change</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">disease</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> commenced dosing the first patient.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Neurology</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">tolebrutinib </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(BTK inhibitor)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The FDA is evaluating under priority review the regulatory submission of tolebrutinib to treat </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">non-relapsing</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">secondary progressive</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">multiple</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">sclerosis</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (nrSPMS) and to slow disability accumulation independent of relapse activity. The target action date for the FDA decision is September 28, 2025. A regulatory submission is also under review in the EU.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Oncology</font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> The study was designed based on treatment effect estimates, assessed using a Bayesian regression, with no testing hierarchy for statistical significance. </font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Applying a frequentist analysis, nominal p-value was 0.0441.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">6</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarclisa</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (isatuximab)</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;padding-left:8.44pt">The MHLW in Japan approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(VRd), </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">for the treatment of adult patients with </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">newly</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">diagnosed</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">multiple</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">myeloma</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> (NDMM) based on data from the IMROZ phase 3 study. In Japan, Sarclisa was launched in August 2020 and has been approved for four different treatment regimens (in combination with pomalidomide and dexamethasone, as monotherapy, in combination with carfilzomib and dexamethasone, or in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma).</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Following the adoption of a positive opinion by the European Medicines Agency&#8217;s Committee for Medicinal Products for Human Use, the EU approved Sarclisa in combination with a standard-of-care regimen, VRd, for the treatment of adult patients with </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">NDMM</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ineligible</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">for</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">autologous</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">stem</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">cell</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">transplant</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (NDMM, TI), based on data from the IMROZ phase 3 study.</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">The National Medical Products Administration (NMPA) in China approved Sarclisa, in combination with a standard-of-care regimen, VRd, for the treatment of adult patients with </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">NDMM,</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">TI</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> based on data from the IMROZ phase 3 study. Earlier in the quarter, the NMPA approved Sarclisa, in combination with pomalidomide and dexamethasone for the treatment of adult patients with </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">MM</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">who</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">have</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">received</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">at</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">least</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">one</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">prior</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">line</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">of</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">therapy</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, including lenalidomide and a proteasome inhibitor.</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Results from the IRAKLIA phase 3 study demonstrated that Sarclisa administered at a fixed dose subcutaneously (SC) via an on-body delivery system in combination with pomalidomide and dexamethasone (Pd) met its co-primary endpoints of non-inferior objective response rate and observed concentration before dosing at steady state compared to intravenous Sarclisa administered at a weight-based dose in combination with Pd in patients with </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">relapsed</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">or</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">refractory</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">(R&#47;R)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">MM</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Additional studies evaluating Sarclisa SC formulations across different combinations and lines of therapy are ongoing. Regulatory submissions in the US and in the EU are planned during the first half of 2025.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SAR445514</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> &#47; </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IPH6401</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (trifunctional anti-BCMA NK-cell engager)</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;padding-left:8.44pt">In March, Sanofi&#8217;s collaborator, Innate Pharma announced that a phase 1&#47;2 study (clinical study identifier&#58; NCT05839626) for the treatment of patients with </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">R&#47;R</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">MM</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> would be terminated early as SAR445514 &#47; IPH6401 would now be pursued in autoimmune indications.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Vaccines</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SP0269 </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(chlamydia)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The FDA granted fast track designation to the SP0269 mRNA vaccine candidate for the prevention of </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">chlamydia</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">infection</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. The decision was based on the potential of the vaccine candidate to address a serious condition and an unmet public health need. Sanofi is starting a phase 1&#47;2 randomized, clinical study designed to evaluate the immunogenicity and safety of the chlamydia vaccine candidate in adults aged 18 to 29 years.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SP0282 </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(E. coli sepsis)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A scheduled review of the E.mbrace phase 3 study (clinical trial identifier&#58; NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi&#8217;s and Johnson &#38; Johnson&#8217;s vaccine candidate for extraintestinal pathogenic E. coli was not sufficiently effective at preventing invasive </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">E.</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">coli</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">disease</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (IED) compared to placebo. No safety signals related to the vaccine candidate were identified and, throughout the study, investigators ensured that participants who developed IED received prompt treatment and care. As a result of the IDMC&#8217;s determination, the E.mbrace study was discontinued. Following the discontinuation, Sanofi recorded an impairment charge of $250 million in the 2024 IFRS results.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nuvaxovid </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(COVID-19)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 23, 2025, Sanofi&#8217;s collaborator, Novavax, Inc. made public that they had recently received formal communication from the FDA in the form of an information request for a post-marketing commitment (PMC) to generate additional clinical data. Novavax will engage with the agency expeditiously to address the PMC request and move to approval as soon as possible. Novavax believes that the BLA is approvable based on conversations with the FDA, as of the Prescription Drug User Fee Act (PDUFA) date on April 1, 2025, and through today.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Anticipated major upcoming pipeline milestones</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Medicine&#47;vaccine</font></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Indication</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</font></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">H1 2025</font></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Dupixent</font></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">BP</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory decision (US)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory submission (JP)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Cerezyme</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">Gaucher disease type 3 (GD3)</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory submission (US)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Sarclisa</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">subcutaneous formulation</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory submission (US, EU)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">MenQuadfi</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">meningitis (six weeks+)</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory decision (US)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SP0087</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">rabies</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 3 data</font></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">7</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.715%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="20" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">H2 2025</font></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Dupixent</font></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">CSU</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory decision (EU)</font></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">itepekimab</font></td><td colspan="3" rowspan="2" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">COPD</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 3 data</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory submission (US, EU)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">balinatunfib</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">rheumatoid arthritis</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 2 data</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Rezurock</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">chronic graft-versus-host disease, third line</font></div></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory decision (EU)</font></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">teplizumab </font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">delay onset of type 1 diabetes</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory decision (EU, CN)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">early intervention in type 1 diabetes</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory decision (EU)</font></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">rilzabrutinib</font></td><td colspan="3" rowspan="2" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">immune thrombocytopenia (ITP)</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory decision (US, EU)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory submission (JP)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Qfitlia</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">hemophilia A&#47;B</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory decision (CN)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SAR447537</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">alpha-1 antitrypsin deficiency (AATD)</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 2 data</font></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">tolebrutinib</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">nrSPMS</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory decision (US)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">primary progressive MS (PPMS)</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 3 data</font></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Sarclisa</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NDMM, transplant eligible (HD7 study)</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory decision (EU)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">subcutaneous formulation</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory submission (JP, CN)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SAR447873</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">gastroenteropancreatic neuroendocrine tumors</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 2 data (final)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SP0087</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">rabies</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory submission (US, EU)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SP0230</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">meningitis</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 2 data</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SP0256</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">respiratory syncytial virus (RSV) (older adults)</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 2 data</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Fluzone HD</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">influenza (50 years+)</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 3 data</font></td></tr><tr style="height:12pt"><td colspan="3" rowspan="23" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</font></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Dupixent</font></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">BP</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory decision (EU, CN)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">itepekimab</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">COPD</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory submission (JP, CN)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">amlitelimab</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AD</font></div></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 3 data</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">lunsekimig</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">asthma</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 2 data</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">frexalimab</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">systemic lupus erythematosus</font></div></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 2 data</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">eclitasertib</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">UC</font></div></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 2 data</font></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SAR444656</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HS</font></div></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 2 data</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AD</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 2 data</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">rilzabrutinib</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ITP</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory decision (CN)</font></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Nexviazyme</font></td><td colspan="3" rowspan="2" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">infantile-onset Pompe disease</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 3 data</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory submission (US, EU)</font></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">venglustat</font></td><td colspan="3" rowspan="2" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">Fabry disease</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 3 data</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory submission (US)</font></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">GD3</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 3 data</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory submission</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SAR447537</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">AATD</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory submission (US)</font></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">tolebrutinib</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">nrSPMS</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory decision (EU)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PPMS</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory submission (US, EU)</font></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">riliprubart</font></td><td colspan="3" rowspan="2" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">chronic inflammatory demyelinating polyradiculoneuropathy</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 3 data</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory submission (US, EU)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Fluzone HD</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">influenza (50 years+)</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">regulatory submission</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SP0125</font></td><td colspan="3" style="border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV (toddlers)</font></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">phase 3 data</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SP0218</font></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">yellow fever</font></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:150%">Phase 3 data</font></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">An update of the Sanofi pipeline as of March 31, 2025, is available at&#58; https&#58;&#47;&#47;www.sanofi.com&#47;en&#47;our-science&#47;our-pipeline.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_40"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:9pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Sustainability update</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Introducing AIR&#58; Sanofi's updated sustainability strategy</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Building on a foundation in corporate social responsibility, Sanofi is introducing an updated sustainability strategy focused on the critical nexus between health and the environment. The AIR strategy addresses three key dimensions&#58;</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;padding-left:8.44pt">A</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ccess to healthcare&#58; expanding sustainable and equitable access to care programs for conditions impacted by environmental challenges, with initial focus on respiratory health and diabetes.</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Environmental impact&#58; reducing the environmental impact of Sanofi&#8217;s medicines and vaccines and activities across the value chain while adapting to climate- and nature-related changes, with the ambition to reach Net Zero greenhouse gas emissions by 2045.</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;padding-left:8.44pt">R</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">esilience of healthcare systems&#58; transforming the delivery of care through treatments and collective efforts that reduce healthcare systems&#8217; environmental footprint.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This strategic focus recognizes that 70% of Sanofi&#8217;s medicine and vaccine portfolio and more than 75% of Sanofi&#8217;s pipeline target diseases that are impacted by climate and environmental challenges, positioning Sanofi to make a meaningful difference through access to care programs and actions to reduce the environmental footprint of healthcare. In these ways, Sanofi intends to contribute to breaking the vicious cycle between environmental degradation and declining human health.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ESG ratings</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s latest ESG rankings&#58;</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><img alt="imagea.jpg" src="imagea.jpg" style="height:281px;margin-bottom:5pt;vertical-align:text-bottom;width:649px"></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">9</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_43"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:9pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Q1 2025 financial results</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business net income</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> were &#8364;9,895 million in Q1 2025 and increased by 10.8% (9.7% at CER) from &#8364;8,933 million in Q1 2024.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> were &#8364;711 million in Q1 2025 and decreased by 10.3% (-11.9% at CER) from &#8364;793 million in Q1 2024. VaxServe sales of non-Sanofi products were &#8364;411 million and decreased by 1.7% at CER. In addition, other revenues included manufacturing services (&#8364;132 million), sales of Opella products in certain markets (&#8364;94 million), royalties (&#8364;39 million), and supply sales to Opella (&#8364;35 million).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Gross profit</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> was &#8364;7,718 million in Q1 2025 and increased by 14.2% (12.6% at CER) from &#8364;6,761 million in Q1 2024. The gross margin was 78.0% and increased by 2.3pp (77.7% at CER, up by 2.0pp). The higher gross margin was driven primarily by product mix and operational improvements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and Development expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> were &#8364;1,808 million in Q1 2025 and increased by 8.3% (6.9% at CER) from &#8364;1,670 million in Q1 2024. This reflected increased activity in mid- and late-stage development as new medicines advanced through phase 3 studies and new phase 2 studies were initiated across the pipeline. An element of the increase related to wind-down costs for the discontinued E. coli sepsis vaccine candidate. The ratio of R&#38;D to net sales was 18.3% and decreased by 0.4pp (18.2% at CER, down by 0.5pp).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> were &#8364;2,222 million in Q1 2025 and increased by 5.3% (3.8% at CER) from &#8364;2,111 million in Q1 2024. This reflected continued support of launches offset by prioritization and efficiency gains. The ratio of SG&#38;A to net sales was 22.5% and decreased by 1.1pp (22.4% at CER, down by 1.2pp).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Total operating expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> were &#8364;4,030 million in Q1 2025 and increased by 6.6% (5.2% at CER) from &#8364;3,781 million in Q1 2024. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income net of expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> was -&#8364;827 million in Q1 2025 compared to -&#8364;597 million in Q1 2024. Income included &#8364;220 million from divestments of medicines&#47;portfolio streamlining (&#8364;134 million in Q1 2024), and &#8364;75 million from license-out royalties and other capital gains (&#8364;54 million in Q1 2024). The income was more than offset by an expense of &#8364;1,062 million representing Regeneron&#8217;s share of profit from the monoclonal antibody alliance (-&#8364;825 million in Q1 2024), -&#8364;58 million from other pharmaceutical collaborators (-&#8364;3 million in Q1 2024), and -&#8364;2 million from other (&#8364;43 million in Q1 2024).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit from associates</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">was &#8364;48 million in Q1 2025 compared to &#8364;38 million in Q1 2024 and included the share of profit related to Vaxelis in the US.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Business operating income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> was &#8364;2,902 million in Q1 2025 and increased by 20.1% (18.7% at CER) from &#8364;2,417 million in Q1 2024, driven by higher gross profit and relatively lower increases in operating expenses. The ratio of BOI to net sales was 29.3% and increased by 2.2pp (29.3% at CER, up by 2.2pp).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net financial expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> were &#8364;68 million in Q1 2025 compared to &#8364;41 million in Q1 2024, reflecting increased net debt and higher average interest rates.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">The effective tax rate</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> was 22.3% in Q1 2025 and increased from 20.0% in Q1 2024. The effective tax rate included a one-off impact from changes in French taxes. Generally, the effective tax rate will fluctuate from quarter to quarter and Sanofi still targets an effective tax rate broadly stable versus 2024 (20%).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Business net income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> was &#8364;2,212 million in Q1 2025 and increased by 15.9% (14.5% at CER) from &#8364;1,908 million in Q1 2024. The ratio of business net income to net sales was 22.4% and increased by 1.0pp (22.3% at CER, up by 0.9pp).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Business earnings per share</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(EPS) was &#8364;1.79 in Q1 2025 and increased by 17.0% (15.7% at CER) from &#8364;1.53 in Q1 2024. The average number of shares outstanding was 1,233.9 million compared to 1,248.8 million in Q1 2024.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Zantac</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During Q1, Sanofi reached agreements in principle to resolve a majority of the Zantac (ranitidine) personal injury cases pending against the company in Delaware. If these agreements, along with the settlements in principle announced in March 2024 outside of Delaware, are finalized, then most of the remaining Zantac product liability cases pending against Sanofi in state courts will be resolved. Sanofi is settling these cases to avoid the expense and ongoing distraction of the litigation. No concessions of liability have been made and Sanofi maintains that the claims are without merit.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Opella</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In February, following completion of the required social and corporate procedures, Sanofi and CD&#38;R signed the share purchase agreement in relation to the sale of a 50% controlling stake in Opella to CD&#38;R. Bpifrance is expected to participate as a minority shareholder with a c.2% stake in Opella, with Sanofi remaining a significant shareholder. The terms of the transaction remain unchanged from those previously communicated, and the closing of the sale is anticipated during the coming weeks as the transaction remains subject to obtaining customary regulatory approvals from the competent authorities.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Q1 2025, and under the new scope of reporting, sales were &#8364;1,318 million and decreased by 4.5% at CER. This performance was impacted by an element of divestment, and phasing&#47;high base of comparison in Q1 2024 from the separation of IT systems.</font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> See Appendix 3 for the Q1 2025 consolidated income statement&#59; see Appendix 9 for definitions of financial indicators, and Appendix 4 for </font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">reconciliation of IFRS net income reported to business net income.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">10</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_46"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reconciliation of IFRS net income reported to business net income (see Appendix 4)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Q1 2025, the IFRS net income was &#8364;1,872 million. The main items excluded from the business net income were&#58;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Net income from Opella discontinued operation amounted to &#8364;174 million.</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">An amortization charge of &#8364;399 million related to intangible assets measured at their acquisition-date fair values of &#8364;386 million (mainly Bioverativ &#8364;156 million, Provention Bio &#8364;55 million, Ablynx &#8364;42 million, Kadmon &#8364;42 million, Beyfortus &#8364;33 million and Genzyme &#8364;20 million) and to intangible assets from separate acquisitions, measured initially at acquisition cost (licenses&#47;products) of &#8364;13 million. These items had no cash impact.</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">A net impairment expense of &#8364;25 million.</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Restructuring costs and similar items of &#8364;105 million mainly related to redundancy plans during Q1 2025.</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Other gains and losses, and a litigation charge of &#8364;37 million.</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">A financial charge of &#8364;59 million related to the remeasurement of expected future royalty on Beyfortus US sales.</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">A &#8364;146 million tax effect arising from the items listed above, mainly comprising &#8364;63 million of deferred taxes generated by amortization of intangible assets and &#8364;27 million associated with restructuring costs and similar items (see Appendix 4).</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash flow</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Q1 2025, free cash flow before restructuring, acquisitions, and disposals amounted to &#8364;1,594 million after a change in net working capital of -&#8364;96 million, and capital expenditures of -&#8364;490 million. After acquisitions</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of -&#8364;623 million, proceeds from disposals</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of &#8364;344 million and payments related to restructuring and similar items of -&#8364;287 million, </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">free cash flow</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:700;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> was &#8364;1,029 million.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net debt</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After the impact of the share buyback of -&#8364;3,609 million and the cash provided by the discontinued Opella business of &#8364;161 million, the change in net debt before Opella reclassification to &#8220;Assets held-for-sale&#8221; was -&#8364;2,315 million. After the reclassification of Opella to &#8220;Assets held-for-sale&#8221; of -&#8364;157 million, net debt increased from &#8364;8,772 million on December 31, 2024, to &#8364;11,245 million on March 31, 2025 (amount net of &#8364;7,991 million in cash and cash equivalents).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the quarter, Sanofi announced that it had successfully priced an offering of &#8364;1.5 billion of notes across two tranches&#58; &#8364;850 million floating-rate notes, due March 2027, bearing interest at 3-month Euribor plus 0.30% and &#8364;650 million fixed-rate notes, due March 2031, bearing interest at an annual rate of 2.75%. The notes were issued off the company's Euro medium-term note program.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shareholder return</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In January, the Board of Directors proposed a dividend of &#8364;3.92 for 2024, marking 30 years of consecutive increases. The proposal is subject to approval at the 2025 annual general meeting on April 30, 2025. Sanofi intends to execute a share buyback program in 2025 of &#8364;5 billion with the purpose of cancellation. As of March 31, 2025, 72% of the program has been completed and the remaining shares will be purchased in the open market.</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:18.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.396%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.993%"><tr><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.248%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.876%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="9" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Media Relations</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Sandrine Guendoul </font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;+33 6 25 09 14 25</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">sandrine.guendoul&#64;sanofi.com</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:justify"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Evan Berland</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;+1 215 432 0234</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">evan.berland&#64;sanofi.com</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:justify"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Nicolas Obrist</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;+33 6 77 21 27 55</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">nicolas.obrist&#64;sanofi.com</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:justify"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">L&#233;o Le Bourhis</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;+33 6 75 06 43 81</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">leo.lebourhis&#64;sanofi.com</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:justify"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Victor Rouault</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;+33 6 70 93 71 40</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">victor.rouault&#64;sanofi.com</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:justify"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Timothy Gilbert</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;+1 516 521 2929</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">timothy.gilbert&#64;sanofi.com</font></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.993%"><tr><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.248%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.876%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="9" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Investor Relations</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:justify"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Thomas Kudsk Larsen</font><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;+44 7545 513 693</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">thomas.larsen&#64;sanofi.com</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:justify"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Aliz&#233; Kaisserian</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;+33 6 47 04 12 11</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">alize.kaisserian&#64;sanofi.com</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:justify"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Felix</font><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Lauscher</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;+1 908 612 7239</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">felix.lauscher&#64;sanofi.com</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:justify"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Keita</font><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Browne</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;+1 781 249 1766</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">keita.browne&#64;sanofi.com</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:justify"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Nathalie</font><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Pham</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;+33 7 85 93 30 17</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">nathalie.pham&#64;sanofi.com</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:justify"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Tarik</font><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Elgoutni</font><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;+1 617 710 3587</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">tarik.elgoutni&#64;sanofi.com</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:justify"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Thibaud</font><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Ch&#226;telet</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;+33 6 80 80 89 90</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">thibaud.chatelet&#64;sanofi.com</font></div></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:justify"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Yun Li</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;+33 6 84 00 90 72</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#23004c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">yun.li3&#64;sanofi.com</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td></tr></table></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Not exceeding &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non-IFRS financial measure (definition in Appendix 9).</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">11</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_49"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:9pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Appendices</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:10.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.448%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_52" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">Appendix&#160;1</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net s<a href="#i14830fdb600a46e3afa7ced50445a7af_52" style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">ales by medicine&#47;vaccine and geography</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_52" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">13</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_58" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">Appendix 2</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B<a href="#i14830fdb600a46e3afa7ced50445a7af_58" style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">usiness net income</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_58" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">14</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_64" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">Appendix 3</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">C<a href="#i14830fdb600a46e3afa7ced50445a7af_64" style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">onsolidated income statement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_64" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">15</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_67" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">Appendix 4</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reconciliation of net income attributable to equity holders of Sanofi to&#160;business net income</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_67" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">16</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_70" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">Appendix 5</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in net debt and summarized statements of cash flow</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_70" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">17</a></font></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_73" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">Appendix 6</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Simplified consolidated balance sheet</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_73" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">18</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_76" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">Appendix 7</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_76" style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">Other operating income net of expenses related to Regeneron</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_76" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">19</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_79" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">Appendix </a>8</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_79" style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">Currency sensitivity</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_79" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_82" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">Appendix </a>9</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_82" style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">Definitions of non-IFRS financial indicators</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_82" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Appendix 10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sustainability dashboards</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><a href="#i14830fdb600a46e3afa7ced50445a7af_88" style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:none">22</a></font></div></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">12</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_52"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Appendix 1&#58; Q1 2025 net sales by medicine&#47;vaccine and geography</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:23.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.071%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025 </font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total sales</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% CER</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% CER</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% CER</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rest of World</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% CER</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immunology</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dupixent</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,480&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20.3&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+22.8&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,476&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+18.4&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">459&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+23.5&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">545&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+26.5&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Kevzara</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+25.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+27.6&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+46.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rare diseases</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fabrazyme</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">262&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.4&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.0&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.4&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.2&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.6&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALTUVIIIO (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">251&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+100.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+105.7&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+83.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+371.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nexviazyme&#47;Nexviadyme (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+26.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+28.3&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+12.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+48.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+33.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cerezyme</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-9.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-11.2&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-6.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-9.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-10.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alprolix</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+23.1&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">128&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+13.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+52.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Myozyme</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">135&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-29.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-29.3&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-21.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-35.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-30.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aldurazyme</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+13.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+13.3&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-8.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+31.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cerdelga</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.6&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-2.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+9.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Eloctate</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-20.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-18.6&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-17.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-29.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cablivi (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+11.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+13.6&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+9.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+8.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+50.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Xenpozyme (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+60.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+60.0&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+33.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+83.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+100.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Qfitlia (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Neurology</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aubagio</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-37.3&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-36.3&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-29.3&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-55.8&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+33.3&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sarclisa (*)</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+26.4&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+28.3&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20.4&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+32.3&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+30.8&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Jevtana</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+7.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.3&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+21.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-50.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-21.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fasturtec</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.8&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+9.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other main medicines</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lantus</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">450&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+24.4&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+25.0&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+68.8&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-18.5&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+17.9&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Toujeo</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">354&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.3&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+14.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+14.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plavix</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.5&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-50.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-4.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lovenox</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">238&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-6.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-9.2&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-13.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rezurock (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">131&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+36.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+40.9&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+31.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+80.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+100.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Praluent</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+6.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+7.4&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+22.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-28.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thymoglobulin</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.3&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-2.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+11.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aprovel</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.8&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Multaq</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.8&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Soliqua&#47;iGlarLixi</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+22.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20.7&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+15.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+27.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+25.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tzield (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.0&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mozobil</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-68.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-68.0&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-66.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-81.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-33.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Others </font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,040&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-8.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-10.6&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-16.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">300&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-12.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">654&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-6.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Industrial Sales</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-35.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-34.4&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-40.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+700.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV (Beyfortus) (**)</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">284&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+54.9&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+56.0&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-44.7&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1014.3&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+131.1&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Polio&#47;Pertussis&#47;Hib primary vaccines and boosters</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">668&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.9&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-9.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+8.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Influenza vaccines</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+420.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+500.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-40.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Meningitis, Travel and endemic vaccines</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">302&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.6&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+21.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-4.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-16.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,895</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+9.7</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+10.8</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,657</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+15.4</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,043</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+0.5</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,195</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+8.4</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharma launches (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">847</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+43.8</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+46.8</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">563</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+38.7</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">162</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+42.1</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">122</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+75.7</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Launches (*), (**)</font></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,131</font></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+46.5</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+49.0</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">628</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+19.9</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">240</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+98.3</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">263</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+101.5</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">13</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_58"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Appendix 2&#58; Business net income</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:15.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="9" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</font></td><td colspan="9" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total group</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2024<font style="font-size:4.55pt;position:relative;top:-2.44pt;vertical-align:baseline">1</font></font></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2024</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2024</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,895</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,933</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10.8</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,895</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,933</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10.8</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">617&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">695&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-11.2&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-4.1&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">711&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">793&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-10.3&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,826)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,907)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-2.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(62)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,888)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,965)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-2.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">As % of net sales</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(28.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(32.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(29.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(33.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross profit</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,686</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,721</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14.4</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">32</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">40</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-20.0</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,718</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,761</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14.2</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">As % of net sales</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">77.7</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">75.2</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">78.0</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">75.7</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,808)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,670)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,808)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,670)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">As % of net sales</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(18.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(18.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(18.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(18.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,200)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,082)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(29)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-24.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,222)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,111)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">As % of net sales</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(22.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(23.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(22.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(23.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income&#47;expenses</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(826)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(604)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(827)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(597)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit&#47;loss of associates* and joint ventures</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,893</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,399</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20.6</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-50.0</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,902</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,417</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20.1</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">As % of net sales</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">29.2</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">26.9</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">29.3</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">27.1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income and expenses</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(68)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(41)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expenses</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(622)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(468)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Tax rate**</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(22.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(20.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:0.5pt solid #330e74;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business net income</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,212</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,908</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15.9</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">As % of net sales</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">22.4</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">21.4</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business earnings&#47;share (in euros)***</font></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-left:1pt solid #ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.79</font></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.53</font></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17.0</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">* Net of tax.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">** Determined based on business income before tax, associates, and non-controlling interests.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">*** Based on an average number of shares outstanding of 1,233.9 million in the first quarter of 2025 and 1,248.8 million in the first quarter of 2024.</font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Figures for Q1 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">14</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_64"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Appendix 3&#58; Consolidated income statement</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2024<font style="font-size:4.55pt;position:relative;top:-2.44pt;vertical-align:baseline">1</font></font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,895</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,933</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">711&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">793&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,889)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,969)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross profit</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,717</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,757</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,808)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,670)</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,222)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,111)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">331&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,158)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(976)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(399)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(484)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Impairment of intangible assets</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(105)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(614)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other gains and losses, and litigation</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(81)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,285</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,236</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(213)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(247)</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">147&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and associates and joint ventures</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,158</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,136</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(481)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(104)</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit&#47;(loss) of associates and joint ventures</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(43)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income from continuing operations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,719</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">989</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income from discontinued operations</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,893</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,146</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,872</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,133</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding (million)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,233.9&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,248.8&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Basic earnings per share from continuing operations (in euros)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.38</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0.78</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Basic earnings per share from discontinued operations (in euros)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0.14</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0.13</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Basic earnings per share (in euros)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.52</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0.91</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Figures for Q1 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">15</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_67"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Appendix 4&#58; Reconciliation of net income attributable to equity holders of Sanofi to&#160;business net income</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2024<font style="font-size:4.55pt;position:relative;top:-2.44pt;vertical-align:baseline">1</font></font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,872</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,133</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income from discontinued operations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(174)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(157)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets<font style="font-size:4.55pt;position:relative;top:-2.44pt;vertical-align:baseline">2</font></font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">399&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">484&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment of intangible assets</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expenses arising from the impact of acquisitions on inventories</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">105&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">614&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial (income) &#47; expense related to liabilities carried at amortized cost other than net indebtedness</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax effect of the items listed above&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(146)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(371)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Amortization and impairment of intangible assets</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(69)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(78)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(3)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(27)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(245)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other items</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(47)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(51)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other tax effects</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other items</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business net income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,212</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,908</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">IFRS earnings per share</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> </font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(&#8364;)</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.52</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0.91</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Figures for Q1 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Of which related to amortization expense generated by the intangible assets measured at their acquisition-date fair values&#58; &#8364;386 million in Q1 2025 and </font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8364;471 in million in Q1 204.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Q1&#58; based on an average number of shares outstanding of 1,233.9 million in Q1 2025 and 1,248.8 million in Q1 2024.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">16</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_70"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Appendix 5&#58; Change in net debt and summarized statements of cash flow</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2024<font style="font-size:4.55pt;position:relative;top:-2.44pt;vertical-align:baseline">1</font></font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business net income</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,212</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,908</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation, amortization and impairment of property, plant and equipment and software</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">349&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">328&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other items</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(380)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(354)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating cash flow</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,181</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,882</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in working capital</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(96)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,713)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment and software</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(490)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(490)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Free cash flow before restructuring, acquisitions, and disposals</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,594</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(321)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Acquisitions of intangibles assets, investments, and other long-term financial assets<font style="font-size:4.55pt;position:relative;top:-2.44pt;vertical-align:baseline">2</font></font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(623)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(219)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items paid</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(287)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(325)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proceeds from disposals of property, plant, and equipment, intangible assets, and other non-current assets net of&#160;taxes</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">2</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">344&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">431&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Free cash flow</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,029</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(434)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Acquisitions<font style="font-size:4.55pt;position:relative;top:-2.44pt;vertical-align:baseline">3</font></font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(83)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Sanofi shares</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition of treasury shares</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,609)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(302)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other items</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(55)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by&#47;(used in) the discontinued Opella business</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">161</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">119</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in net debt before Opella reclassification to &#8220;Assets held-for-sale&#8221;</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,315)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(741)</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Impact on net debt of the reclassification of Opella to &#8220;Assets held-for-sale&#8221;</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(157)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in net debt</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,472)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(741)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Beginning of period</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,772</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,793</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Closing of net debt</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,245</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,534</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2024</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">1</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) continuing operating activities</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,908&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(46)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) operating activities of the discontinued Opella business</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;text-indent:49.6pt;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by&#47;(used in) operating activities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;text-indent:49.6pt;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,093</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">88</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) continuing investing activities</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(767)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(363)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) investing activities of the discontinued Opella business</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by&#47;(used in) investing activities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(776)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(372)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) continuing financing activities</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(584)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">760&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) financing activities of the discontinued Opella business</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by&#47;(used in) financing activities</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(592)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">760</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of exchange rates on cash and cash equivalents</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Impact on cash and cash equivalents of the reclassification of the Opella business to &#34;Assets held for sale&#34;</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(154)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">550</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">471</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalent, beginning of period</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,441</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,710</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalent, end of period</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,991</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,181</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Figures for Q1 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Free cash flow includes investments and divestments not exceeding a cap of &#8364;500 million per transaction (inclusive of all payments related to the </font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">transaction).</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Includes transactions that are above a cap of &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">17</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_73"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Appendix 6&#58; Simplified consolidated balance sheet</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:19.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.878%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.079%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">liabilities and equity</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2024</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #330e74;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Equity attributable to equity holders of Sanofi</font></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">74,074</font></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">77,507</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Equity attributable to non-controlling interests</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">344</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">350</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity</font></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">74,418</font></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">77,857</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Long-term debt</font></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">11,767</font></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">11,791</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Property, plant, and equipment &#8211; owned assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">9,819</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">10,091</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Non-current lease liabilities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">1,644</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">1,645</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Right-of-use assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">1,533</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">1,510</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Non-current liabilities related to business combinations and to non-controlling interests</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">556</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">569</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Intangible assets (including goodwill)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">63,809</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">66,013</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Non-current provisions and other non-current liabilities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">7,690</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">8,096</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Non-current income tax assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">562</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">560</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Non-current income tax liabilities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">1,532</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">1,512</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Other non-current assets, investments in associates and joint-ventures and deferred tax assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">12,150</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">12,036</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Deferred tax liabilities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">2,064</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">2,166</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets</font></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">87,873</font></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">90,210</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current liabilities</font></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">25,253</font></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">25,779</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #330e74;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Accounts payable and other current liabilities</font></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">21,616</font></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">21,792</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Current liabilities related to business combinations and to non-controlling interests</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">0</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">72</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Inventories, accounts receivable and other current assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">21,850</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">20,934</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Current income tax liabilities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">783</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">697</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Current income tax assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">447</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">724</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Current lease liabilities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">265</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">261</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Cash and cash equivalents</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">7,991</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">7,441</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Short-term debt and current portion of long-term debt</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">7,371</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">4,209</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Assets held for sale</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">13,731</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">13,489</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Liabilities related to assets held for sale</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">2,186</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">2,131</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current assets</font></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">44,019</font></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,588</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current liabilities</font></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">32,221</font></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">29,162</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total assets</font></td><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">131,892</font></td><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">132,798</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity and liabilities</font></td><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">131,892</font></td><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">132,798</font></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">18</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_76"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Appendix 7&#58; Other operating income net of expenses related to Regeneron </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2024</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Monoclonal antibodies alliance</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income and expense related to profit&#47;loss sharing</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">(1,115)</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(868)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional share of profit paid by Regeneron related to development costs</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">222</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;text-indent:10pt;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">174</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regeneron commercial operating expenses reimbursement</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">(169)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;text-indent:10pt;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(131)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total&#58; monoclonal antibody alliance</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,062)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(825)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other Regeneron</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total others related to Regeneron (mainly Libtayo</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> </font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">and Zaltrap)</font></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">35</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">51</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-bottom:0.5pt solid #330e74;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total related to Regeneron</font></td><td colspan="3" style="background-color:#7802e6;border-bottom:0.5pt solid #330e74;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,027)</font></td><td colspan="3" style="background-color:#7802e6;border-bottom:0.5pt solid #330e74;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(774)</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">19</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_79"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Appendix 8&#58; Currency sensitivity</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">2025 net sales and business EPS currency sensitivity</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:55.910%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Currency</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Variation</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales sensitivity</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business EPS sensitivity</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">US Dollar</font></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.05 USD&#47;EUR</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-&#8364;968&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">m</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;-EUR 0.18</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Japanese Yen</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5 JPY&#47;EUR</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-&#8364;55&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">m</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;-EUR 0.02</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chinese Yuan</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.2 CNY&#47;EUR</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-&#8364;69&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">m</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;-EUR 0.02</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Brazilian Real</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.4 BRL&#47;EUR</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-&#8364;53&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">m</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;-EUR 0.01</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Currency exposure on Q1 2025 sales </font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.794%"><tr><td style="width:1.0%"></td><td style="width:84.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Currency</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">US Dollar</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48.0&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Euro</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.7&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chinese Yuan</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.9&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Japanese Yen</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.5&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Canadian Dollar</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.5&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Russian Ruble</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.2&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkish Lira</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.1&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Brazilian Real</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.1&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Australian Dollar</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.3&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">British Pound</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.2&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Others</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.5&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Currency average rates</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:55.910%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;&#47;$</font></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.085&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.053&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #330e74;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-3.0&#160;</font></td><td style="border-top:0.5pt solid #330e74;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;&#47;Yen</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161.152&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160.396&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-0.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;&#47;Yuan</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7.821&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7.666&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-2.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;&#47;Real</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.375&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.160&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+14.6%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;&#47;Ruble</font></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98.637&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98.140&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-0.5&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">20</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_82"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Appendix 9&#58; Definitions of non-IFRS financial indicators</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Company sales at constant exchange rates (CER)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">References to changes in net sales &#8220;at constant exchange rates&#8221; (CER) means that it excludes the effect of changes in exchange rates.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The effect of exchange rates is eliminated by recalculating net sales for the relevant period at the exchange rates used for the previous period.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Reconciliation of net sales to company sales at constant exchange rates for Q1 2025</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.794%"><tr><td style="width:1.0%"></td><td style="width:84.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,895</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of exchange rates</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Company sales at constant exchange rates</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,797</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Business net income</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi publishes a key non-IFRS indicator. Business net income is defined as net income attributable to equity holders of Sanofi excluding&#58;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">net income from discontinued operations,</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amortization of intangible assets,</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">impairment of intangible assets, </font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">fair value remeasurement of contingent consideration related to business combinations or to disposals,</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">expenses arising from the impact of acquisitions on inventories,</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">restructuring costs and similar items</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">,</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">other gains and losses (including gains and losses on disposals of non-current assets</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">),</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">costs or provisions associated with litigation</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">,</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">financial (income)&#47;expense related to liabilities carried at amortized cost other than net indebtedness, </font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">tax effects related to the items listed above as well as effects of major tax disputes,</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the share of profits&#47;losses from investments accounted for using the equity method, except for joint ventures and associates with which Sanofi has a strategic alliance,</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">net income attributable to non-controlling interests related to the items listed above.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Free cash flow </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Free cash flow is a non-IFRS financial indicator which is reviewed by management, and which management believes provides useful information to measure the net cash generated from Sanofi&#8217;s operations that is available for strategic investments</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (net of divestments</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), for debt repayment, and for capital return to shareholders. Free cash flow is determined from the Business net income adjusted for depreciation, amortization, and impairment, share of profit&#47;loss in associates and joint ventures net of dividends received, gains and losses on disposals, net change in provisions including pensions and other post-employment benefits, deferred taxes, share-based expense, and other non-cash items. It comprises net changes in working capital, capital expenditures and other asset acquisitions</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> net of disposal proceeds</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, and payments related to restructuring and similar items. Free cash flow is not defined by IFRS, and it is not a substitute measure for the IFRS aggregate net cash flow in operating activities.</font></div><div id="i14830fdb600a46e3afa7ced50445a7af_85"></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Reconciliation from net cash provided by&#47;(used in) operating activities to free cash flow</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;Q1 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2024<font style="font-size:4.55pt;position:relative;top:-2.44pt;vertical-align:baseline">4</font></font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;letter-spacing:-0.005em;line-height:100%">Net cash provided by&#47;(used in) operating activities excluding the discontinued Opella business</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;letter-spacing:-0.005em;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">5</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,094</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">88</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) operating activities (IFRS) of the discontinued Opella business</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(185)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(136)</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition of property, plant, and equipment and software</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(490)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(490)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of intangibles assets, investments, and other long-term financial assets</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">3</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(623)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(219)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from disposals of property, plant and equipment, intangible assets, and other non-current assets net of&#160;taxes</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">3</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">344&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">431&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayment of lease liabilities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(63)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(73)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Others</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(35)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;letter-spacing:-0.005em;line-height:100%">Free cash flow<font style="font-size:4.55pt;position:relative;top:-2.44pt;vertical-align:baseline">6</font></font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,029</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(434)</font></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Reported in the line items Restructuring costs and similar items and Gains and losses on disposals, and litigation.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Amount of the transaction above a cap of &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Not exceeding a cap of &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Figures for comparative period (2024) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Most directly comparable IFRS measure to free cash flow.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non IFRS indicator (see definition in Appendix 9).</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">21</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_88"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Appendix 10&#58; Sustainability dashboard</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Data are presented as year to date unless stated otherwise. While Sanofi is transitioning to the updated strategy and evolving the KPIs, the company continues to provide quarterly data on the key indicators below.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.948%"><tr><td style="width:1.0%"></td><td style="width:16.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.329%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Topic</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ambition</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Progress</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #330e74;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2024</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Global Health Unit</font></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reach 1.5 million NCD patients by 2026 (cumulative since 2022) and 2 million by 2030<br></font><font style="font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><br></font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83,228 patients treated in 21 countries<br></font><font style="font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85 active healthcare partnerships in 30 countries<br></font><font style="font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 investments signed through the Impact Fund</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57,889 patients treated in 18 countries<br></font><font style="font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44 active healthcare partnerships in 21 countries<br></font><font style="font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 investments signed through the Impact Fund</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Polio</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provide inactivated polio vaccines (IPV) to UNICEF for Gavi countries to support polio eradication efforts</font></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.7 million IPV doses supplied to UNICEF for GAVI countries</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.4 million IPV doses supplied to UNICEF for GAVI countries</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #330e74;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2025</font></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q4 2024</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Climate change &#8211; carbon footprint </font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(CO</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:0.98pt;vertical-align:baseline">2 </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">emissions)</font></div></td><td colspan="3" style="border-top:0.5pt solid #330e74;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55% reduction in scope 1 and 2 greenhouse gas (GHG) emissions (CO</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:0.98pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> equivalent) by 2030 (cumulative versus 2019 baseline) to contribute to carbon neutrality by 2030 and net-zero emissions by 2045 (all scopes)</font></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44% GHG reduction versus 2019</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47% GHG reduction versus 2019</font></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Global gender balance</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gender parity in senior leadership roles</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46%</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46%</font></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40% of women in executive roles</font></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44%</font></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:11pt;font-weight:400;line-height:120%">End.</font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> As of 2025, Sanofi&#8217;s environmental reporting excludes Opella data.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">22</font></div></td></tr></table></div></div></div><div id="i14830fdb600a46e3afa7ced50445a7af_91"></div><hr style="page-break-after:always"><div style="min-height:53.86pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-looking statements</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words &#8220;expects&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;intends&#8221;, &#8220;estimates&#8221;, &#8220;plans&#8221; and similar expressions. Although Sanofi&#8217;s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi&#8217;s ability to benefit from external growth opportunities, to complete related transactions and&#47;or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; in Sanofi&#8217;s annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All Sanofi trademarks mentioned in this document are protected.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PRESS RELEASE</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%"> Q1 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">23</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>fsridynmyoja6nwywy2m1otazoa.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fsridynmyoja6nwywy2m1otazoa.gif
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M9FD1DEANF5"4;J5DY(==WJ6@E[V)>6.:A:D$9G)N/F?GG7CFJ>>>?/;IYY^
M!BKHH(06:NA52S9%YE.'-NKHHX1:J>BB84%JZ:68^J59;A11ZE2FH(8JJE%G
MCFKJJ:CV.:>=<'(U5*M]3?\):V)5P;K<K % 6*=6N*ZJ4*\D'@ELL/\-2]^:
MMJI'I;+& L9ELZ46!*V-6D[K;)MPQL@F ,3*&ABVT>JZK+#;DALN="Y:F.Z&
MNSHI8[=TP>MNN;^>JVV[X/G*+K[YTOOLM<Q>B96\;QYH[K@% YR?O=2!J>^^
M!M\+K+=_W>HOA0P'7#&:"+?D<,8<*UPEM"-'3#%?878<6ZD$%VNRN"^[++)=
M74*L\LH7CP@RKSFCN[-[JS[<(K^UAB?QNN#&O'#/0]^\-+5T(MVTT@EOW*.G
MG\H\<\C6HAPUU1T2?737L29M]8!$8QV5UEY72S:M#3/-==LXDQWBSS!OO1#6
M:.O_??)L)3J-GN!]GR:4W%_3G>KBC#?N^..01R[YY)17;OGEF&>N^>9_FZ@V
MYZ"'#NE\#ZG-D^BHI[[GD).:_I;JL,<NF*2MNRZE[+CG7C3M7]DN@.[ !Q^4
MU"5]+OSQR!?N=_+,-Q\HWLY'+_W B \*M:I[&;H\H+917_V=N"*:[.$3GY4A
M9^'GK?C!;WO\-DW(O@^_8L,J7[/&ZS\M/U)U[]]8ROY+BL7:5S7>\4QL)PK@
ML4JFP/_%K8$+'!P$)=@J]>6O7Q!T( ,S>)/$<;"#ZOI@G/YU/Z AD%N;LAGA
M]!<:_!&/A=<SH7%(&$.=&6Z#%[Q;N5KF-@&:[80PW)X+_]74OXQE)FP\'&+W
M[)?#!'[O@4@$XI<8)K3^Z.N%/5RA%9\XM^S)$&R:JN(7A3C&L\U+;DD,H12%
MM$8 DE$@-0PC%RWHQ0=J\8=U["(1W1<M,8[-C!@T&EG\J$0-L>^-.,SC'YO(
M-D4NTI&=6^(!2;<BZ)61D85T520-^<@]LH=EEIPD&#&6/B9"LI&>G.(<M[C&
M-!;PE*)$9!1E:4.247"4\<,E*^^8R%32T9>!:R,A,UDV.S8KBYC,)2V3U,:I
M+=-GS>PE,"\)RU=.4YK9,J8N:5C-7TKRC+QTXBJ#F$QFAA.9W01G"9WY3&T"
MDIWEQ*8FX1E/=*8SD-NTYS>)0O\D>M;3@_\T9S[=&5!QCE.@YZQE0O%X3:L(
M3(_M[.0^(<I)=4:4C<.$8QPE6M%-SC,B49+3$?UIKQ02])X,G2A%%ZI10:JP
MH/(LYMY<Y]&.>E.$;GSG+2^J4!&.,*<P!2I*?7<[5*J4HQ,$*$IC&D&A^D^-
M TVI30M"5)W4M*F'S"!3X6;-HSK5ECO5J0[31E0SA9*#W&SH+,4*U?*-E:5?
MG>I!;&?6@]:K?EV5ZUJ#&E?5?-*NL63K3,M$N19.[Z^A/*QB%\O8QCKVL9"-
MK&0G2]G*6O:RF,WL89?:NZQI]K.2=>G5R 3:TD9O-9WEFVE7JSO C=9TK(UM
MZOK)D*K_RO:VF6-=[6B*V]Y*3DF[Y:UOA[NX=2JDJD4EKG)%9=S!^FZYT 55
MFE(KW.A:UU'3!2E=K\O=0VT4)-7MKGBYE]'@5FJ\Z"4O8"5RWO2Z]T^)?:]\
MBQO?^=IW5/6]KWXSE=_]^A>[_5W=1__[WO(^![4'-FE>#,LG RM5K=YMKD.!
M.V$)FP_!PYL5.;V:U6R2"J\#--8@#1C,"A(3JZKL6GWD9U$"5G)\(M7PB;F:
MXJ?658'Z='&&17QC$U,3PH&U<1$;*-7]T<QN;_5PD#G;4ZTJT\DGA7*/=?QD
M$N,SHC[]5HX#V%<<7Y7'5:;PCSE,RBSO]8-=]G*+N=Q6"Y=Y_Z%9_NE6A=QA
M,X<UJ6D]WXQ]>%,ZIYG(#\9IF]&<9]HN&<@8%2TT%?QG0$?9IV<F])P?VF>9
MWA6+&];K2J,J+4:_E---=N6>F=Q216\:Q7D=\)5!O><M\W75@ATU_\+,TTZ/
M--"U7C2K'ZUI7>^:I+DJ,J+K/&Q8D_K4J@;VL<?\:E_'^LY+=? N/U/H8A.;
MS(?&-J^U?>GZ?E?6(#3EL*6-V  _C-PH+*FH<<WM-_^ZQKI$-Q_7&^IFEQJN
MR.;SI^V-U&3W&]5KCK:\8TSO>B_;H.^N-,"-S>],6QOAN=ZWMC$]NX(;_.'N
MCCBXYZ=L?R>9IP.WM=AN/9=U"WOAS/_V^* /;G)76WKC6A8WMV<H1WQ?N]?9
MQOFD-?AOE _YV0@%^LJ+C>$16_SB[0YZPU/^\IRKW*@Z1WK474YCAM-\*BW?
M>;CAK7&F^USJ3X=ZV)5^<'8WG>R)VG$T;SYVIY\]TDEW]M*Y+G2(UYWJ^H:Y
MJ3]^]VJ_7>_4%OO?,]YUN@<UY(ENYS&G7/B>YUWB4]_VX,'>]H!C_-X)[_C7
M*6]EN$?^Y%7/]ZP%OWF1VUSK''?XYU$?<\V[6?*E]WOL"3_W:6,YP-T&->+E
M7G;3+Q[TH4_UY&W?=[8/W^ZU=_WC 1_L$F>>]Z4T^^P;/7KC3Q_RE4=^[ZG/
M<\=7G^"G1SO_C V_?>P?/_>-M_KJTWUT\:^?_>$W__6]7QO8SY_\E]=^_I7_
M??IO'?SXMGN8EW[$EUWR=W_\UWT)^'\_QU=9QWIRIGK9AW?]YWRZM8 *V(#E
M!W_/YW;W]X#V%WQ>)X*6%W=\5W02^'ZBEX$IB(#^EWHK6($:N'T"R($$Z'D4
MYW[[UX(DR'R,5WR^%W\>.(&<UX/0MH/S=G4O*(,4R()+&($S:()!*(0Z*(6)
M!X3<QX!CP6 \J((%R&\#=T4D!X%.J'!&2&M6V%Y?MGY<F(5,^(2!=X(;J(0'
M:(53F'P^J%V+\H,!Z%=P>(9?B(1_"'Q"=T-NV'I\R%GA%86]%V?+_Q>#,%B"
M7GB'DG:(4$AZ@/A<:_B(9JAFU@>(EAB'H0AF9-A\,H=SMH6)H%B%CO:)G#AT
M=DA[K5B*(89+R+6)9=B)+"9]JQB";^B*O]>$6BB'0(9<OZ.*O]B%5%:'R2A[
MO?B'G4>(N7B$V':+R#B-RC@MM(B+PRB-!DB-D\B,V&B-Q!B+K*B-VWB-W>B,
MK\>.S8B&J%A6W(B(.$B*HYB(@@B-="B)1.B-D3@FVZ6._PB//@:+X9B'I^A:
M 'B#0_B*<V4\\WB)PI=V$^F0]?B,%SF&%HB'"$E=/I*$&SB*(0F,$LF/V+B1
C(,B(%EF.&$E5:Z,Y5$A<'$E@-%F3-GF3. >9DSKI6 $! #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>imagea.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imagea.jpg
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M  0!&@ %     0   #X!&P %     0   $8!*  #     0 "  "':0 $
M 0   $X         D     $   "0     0 #DH8 !P   !(   !XH ( !
M  $   =XH , !     $   ,\     $%30TE)    4V-R965N<VAO="1A0"<
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M$$   03J1(" MTYV%,U$  $$$$   0000  !!!!   $$$$   0000  !!!!
M  $$"'AY#R"   ((((   @@@@  """"   ((((   @@@@  """"   )U(D#
M6R<[BF8B@  """"   ((((   @@@@  """"   ((((   @@@@  "!+R\!Q!
M  $$$$   0000  !!!!   $$$$   0000  !!!!  ($Z$2#@K9,=13,10  !
M!!!   $$$$   0000  !!!!   $$$$   0000  ! E[> P@@@  """"   ((
M((   @@@@  """"   ((((   @@@@$"="!#PULF.HID(((   @@@@  """"
M  ((((   @@@@  """"   ((((   2_O 0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000*!.! AXZV1'T4P$$$   0000  !!!!   $$$$   000
M0  !!!!   $$$$" @)?W  ((((   @@@@  """"   ((((   @@@@  """"
M  (((% G @2\=;*C:"8""""   ((((   @@@@  """"   ((((   @@@@  "
M""! P,M[  $$$$   0000  !!!!   $$$$   0000  !!!!   $$$*@3 0+>
M.ME1-!,!!!!   $$$$   0000  !!!!   $$$$   0000  !!! @X.4]@  "
M"""   ((((   @@@@  """"   ((((   @@@@  ""-2)  %OG>PHFHD  @@@
M@  """"   ((((   @@@@  """"   ((((   @@0\/(>0  !!!!   $$$$
M 0000  !!!!   $$$$   0000  !!.I$@("W3G84S40  0000  !!!!   $$
M$$   0000  !!!!   $$$$   00(>'D/((   @@@@  """"   ((((   @@@
M@  """"   ((((   G4B0,!;)SN*9B*   ((((   @@@@  """"   ((((
M @@@@  """"   ($O+P'$$   0000  !!!!   $$$$   0000  !!!!   $$
M$$  @3H1(."MDQU%,Q%   $$$$   0000  !!!!   $$$$   0000  !!!!
M  $"7MX#"""   ((((   @@@@  """"   ((((   @@@@  """" 0)T($/#6
MR8ZBF0@@@  """"   ((((   @@@@  """"   ((((   @@@@  !+^\!!!!
M  $$$$   0000  !!!!   $$$$   0000  !!!! H$X$"'CK9$?13 000  !
M!!!   $$$$   0000  !!!!   $$$$   0000(" E_<  @@@@  """"   ((
M((   @@@@  """"   ((((   @@@4"<"!+QULJ-H)@((((   @@@@  """"
M  ((((   @@@@  """"   ((($# RWL  0000  !!!!   $$$$   0000  !
M!!!   $$$$   000J!,! MXZV5$T$P$$$$   0000  !!!!   $$$$   000
M0  !!!!   $$$"#@Y3V   ((((   @@@@  """"   ((((   @@@@  """"
M  ((U(D  6^=["B:B0 """"   ((((   @@@@  """"   ((((   @@@@  "
M"!#P\AY   $$$$   0000  !!!!   $$$$   0000  !!!!   $$ZD2 @+=.
M=A3-1  !!!!   $$$$   0000  !!!!   $$$$   0000  !! AX>0\@@  "
M"""   ((((   @@@@  """"   ((((   @@@@  "=2) P%LG.XIF(H   @@@
M@  """"   ((((   @@@@  """"   ((((   @2\O <00  !!!!   $$$$
M 0000  !!!!   $$$$   0000 "!.A$@X*V3'44S$4   0000  !!!!   $$
M$$   0000  !!!!   $$$$   0)>W@,(((   @@@@  """"   ((((   @@@
M@  """"   ((((! G0@0\-;)CJ*9"""   ((((   @@@@  """"   ((((
M @@@@  """"   $O[P$$$$   0000  !!!!   $$$$   0000  !!!!   $$
M$$"@3@0(>.MD1]%,!!!   $$$$   0000  !!!!   $$$$   0000  !!!!
M@("7]P """"   ((((   @@@@  """"   ((((   @@@@  """!0)P($O'6R
MHV@F @@@@  """"   ((((   @@@@  """"   ((((   @@@0,#+>P !!!!
M  $$$$   0000  !!!!   $$$$   0000  !!!"H$P$"WCK94303 0000  !
M!!!   $$$$   0000  !!!!   $$$$   000(.#E/8   @@@@  """"   ((
M((   @@@@  """"   ((((   @C4B0 !;YWL*)J)  ((((   @@@@  """"
M  ((((   @@@@  """"   (($/#R'D   0000  !!!!   $$$$   0000  !
M!!!   $$$$   03J1(" MTYV%,U$  $$$$   0000  !!!!   $$$$   000
M0  !!!!   $$"'AY#R"   ((((   @@@@  """"   ((((   @@@@  """"
M  )U(D# 6R<[BF8B@  """"   ((((   @@@@  """"   ((((   @@@@  "
M!+R\!Q!   $$$$   0000  !!!!   $$$$   0000  !!!!  ($Z$2#@K9,=
M13,10  !!!!   $$$$   0000  !!!!   $$$$   0000  ! E[> P@@@  "
M"""   ((((   @@@@  """"   ((((   @@@@$"="!#PULF.HID(((   @@@
M@  """"   ((((   @@@@  """"   ((((   2_O 0000  !!!!   $$$$
M 0000  !!!!   $$$$   0000*!.! AXZV1'T4P$$$   0000  !!!!   $$
M$$   0000  !!!!   $$$$" @)?W  ((((   @@@@  """"   ((((   @@@
M@  """"   (((% G @2\=;*C:"8""""   ((((   @@@@  """"   ((((
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MX;Z'V3X$1I9 ]0 B >_(VN]L+0+#48#^;#CN5;8)@9$I4.W/"'A'YOYGJQ%
M8' %"'@'UY.U(8# "!0@$!F!.YU-1F"8"M"?#=,=RV8A,$(%J@<0"7A'Z!N
MS49@& G0GPVCG<FF(##"!:K]&0'O"'\CL/D((# H @2\@\+(2A! 8"0+$(B,
MY+W/MB,PO 3HSX;7_F1K$!CI M4#B 2\(_V=P/8C4/\"]&?UOP_9 @00J A4
M^S,"7MX1""" P/,7(.!]_H:L 0$$1K@ @<@(?P.P^0@,(P'ZLV&T,]D4!!!0
M]0 B 2]O!@00J'<!^K-ZWX.T'P$$J@+5_HR MRK";P000&#+!0AXM]R.)1%
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M22NOKASI^=G4V+6\#GH)>%="\6L(!*KO<0+>(<#F)1! 8-@+$/ .^UW,!B*
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MBMTPJ+/CW4JXZTKA:/FPCO##!8&M*%#MSPAXMR(RJT8 @1$C0, [8G8U&XH
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M'?@FVQ1O\-Q(J58'R Y[%<)>+@C4EP#]67WM+UJ+  (;%J@>0"3@W; 3CR*
M0.T+T)_5YCX*\]B&2RD$I[Z>\-#,?85^??6\KZO87-!C3]WG*MFE:DZ7M,?T
M73W4\7::.W= 32T>JMDG'<<]K''&\_$V-674D$FKU4,C)XIEGV3LYSC<361:
M-:YIM&[Y[5]TPLN.UXU__9MFKUB@=Y[^7LU=.E?Y4K^?U[!R^.5*I6Z8AS?K
MX#94Z89PMS(';PA[*VW,^?X0\%8#X-#N$/R6' CG"P-^GD]XCC>JK[>H;'9
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M<A"=Z^E682"O_?8Z4&><_GFE D8^[J&GDR[5#%Y<$'BN0+4_(^!]K@NW$$
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MO[??)QOV^^3#UK96A[_='IXYZ\ W##T=JG4]IV^8JW>-@->)M4/E ?7[L>Q
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MV%$_^LW)ZWVE+WSR"EWGH8KW\5RX%USY@:A=5UY^E[YVQA]=+3Q:7_[.&W7
M(=/6NWQX('R?"._=3@>\I[_WE[K_]MEZR=&[Z'N7GN26;.A;?!BU+\P)O,'5
M/^?!IV8MUH?><;$&'/"^ZW0'O!\ZXCF/AQLS'YBC4T(%KZ^?]OD0\+YPK>>$
M.QZ;.5\??=>E#GC[]=EO.>!]0ZC@Y3*<! AXA]/>9%MJ4N#O-\_1;ZY^0M==
M/T?_^[%]];$/[?-L.Q]_<H6NOF&V7G30!!URP 2=?\%]#H&GJK4IHZO_])3V
MW7>T7GS(Q&?_"'SARW?JG!_<K[%C&G3:!_;0)T[=SU7!?&1^%G0;72$0V4;P
M-1'P5K?='R[#)^&X*WK3GE\IW:Y2WSP5LYZ_-ZKDW=1/<OYZW3A)B9:IU17S
M&X$A%: _VPBW_SLO^T!9].7.!]U\1&RCE^B+7/AG/=_HBC[H=N^YW]&\:Z]5
MS@?,<CZ MBD]!@'O1NEY @+^SZ[R7Q,!+V\&!!"H=P'ZL]K8@V&NVC!M3_0A
M,/H3D]"M]]VI[UQTKI9E%RO1[(#6HSM-&+6=4AZA)98INRHVKP:GG8E,2B4/
MN=RHE)KCC7[,06Y4L>O?*ZMV,Z[P#>%NN1CFZ8UYZJX>M31N[^L-*L:?4*+U
M*<>Q#F^S.[IJ:WN'KOYLFO 41'%7WQ;2;I?76_9S';267.D;YN3-E_K]]W"I
MQG8,^#-L6G/GY5REVZH!S\7;/Y!U")U6UL,TQZ-Y,D/E;MYAKZ<0*>1=X5MV
MH!SF]O6PS0YX\QZ:N3B0=U5>6=E$T5]_4XKWQ)286U!FOF<!]BATT_?;4U_[
M\3>5\ AV7!!8ET"U/R/@79?.MKPO?+F-:?[<93K'0R;/N.UI#?1FW9?X;@\9
M/VI<@UY\Q,XZ\3V':LFB7IW]F=^[:K=?WW3 >T0UX/W@KW1?J.!UP/N!C[_,
M0>K&O]E6 MYK=.UO_Z/C'/!^<3,"WE-/^KEF_&N6INTZ7N_[Y,O<3_FDE7!L
M;N4EO-="&RZ[Z%8_[RGMML<D77S-!ST7>D)_O_Y^?=%S\!:S11UR^,XZW//P
M9IJ3T:&]L'@XCR>LJZ6M6?MZSMO1'B8_7,))VI_^R!6Z_<;'//Q]3"][PUXZ
MZ$73_=K%9P\/5-H0TPX[C/=\N9.C_C5:>!/_V;2 =VX4\/K/A3YVYK%ZTXF'
MK'/MCSTT7Z>^NQ+P?HZ =YU&]7XG 6^][T':7Y,"2Y=E/93R'/4.^)1)'ZC=
M9==VW7[G(IWXYITU:6)SU.:9CR[3-7^9K:,.GZ*#/<= =V]>%__J(1UUV&3M
ML^=8S7ZZRZ'PT]IOWS%ZR8LG1LO,<R7O-[_W'[5[DO:##ABK'L]3\,JC=U!'
M6Z8F'49*HPA$MM&>KJF MVI0^4"L9+L239-=R;M Q;[J$,\;_V ;'2AP2)P<
MM;.'WZI4^5?7S&\$AD* _FS#RF4?+.N?/4=+K[\Y"HX*T<AY&_IOVV?YYHMJ
M?\D+U+K/;A[2?=VC 80OB?>=_T,]<]654<5$UI\=-G9(C(!WP_N*1Q$( M4#
MB*L?Z$$& 000J$<!^K-:V&MA(&.?B.?JV' I.^2,^1/;/^ZY5=^Y^#OJ*G0J
MV9QQL#E*S3%7\OJQMNW:');V23T#2C?ZL?86-7A8YV1!2C<U*AY5\#K@=0B1
M=.5N0QB^V2%P"''SG@\W'AM0<],XOYI?,[Y(Z=9.ARTQ%7/C/&)4N\,$!PKE
MW,J\.1Y5WP[D"O[[YT* N!\M._@M]WD.X#Z-'E7V'+S]6K;" 49\C/IR86F'
MMF%(9W_&+>;"O+MY3QWDDXX=]N8=\(;@-\S1&W< 78R&:_9<8_D0'GO^70\+
M'6],1D.(CNKTUL[)J[ BIPG3)NG;%WQ/#<T;J\"+&/EG! I4^S,"WMK;^7F?
MW''J2:Y.O>,I]TDQM8UM5EMKQCV?^P@GO7G_]Q_ZHP$/"YSU"1U]N9*^\:.W
MZHB7KZS@=<#[7P>\)W_4 >\GMG[ &RIX[[O-)[^X_^SSR2=K3946OJK[I)RT
MMV6@OZ 7'C5=W[OX)/=QTK*EW3KOZS?HNM_-\+SG85_$/.R^3YH)5WV)>T2$
MT/6&OG37O;?3Q\]\M?8[<(?HL1EW/ZDO?^(/6CAO>32H0SCO9]6284WA;E?M
M>ODWON,@G>;Y<3.-X22<3;L0\&Z:$\^J"!#PUO@[H>@#?(\\^JARGL<B_ $,
MPZ,T-S=KIYVF16?Z;6[SPTDW#SWP4'162=39A#-16ELT;=K4:*Z/S5G?D[.>
MTJQGYFKNW 4^NS"G5%.+)H\?JZE3)FO''0>_^FS)DB4./>?JF06+U-W3$WE,
MV6Z")F\W7E.VG^0/K(V;TWS/A3M'#\Q\U!]@W>6&CM@]^,N//,SSVGKXG.=Y
M^>DO'M(9I]^N PZ?H#]?\2IU]>1US9]GZW7'[:!VA[$//[9,?_KK,SKFT,DZ
M8-^QT:OU.."]:+6 -]PY9VZ/KKQJEO;WD,Z''S8I>MY-M\Z)YO)]R<&3],<_
M/Z5'GEBAD]ZZN\:/??[MCEZ ?S9;@$!DL\D&9X&:#'A7;EH8MCG>HF3K3CZ[
M>I&*O;/]"6_=P<ZZ,&*I#@_5O+.7B3YEKNLIW(? 5A&@/]LX:W;>0CW]@XM5
MNO'?/KY54K_G-XN'#U7KN8SQ?&O)DUZO22>]68D-?,8H^8S?!R_\F6;]^M>N
MP"AXO1L.>0EXUP/.W0BL)E ]@$C NQH*5Q% H"X%Z,]J8;>M&?"&P_<)W7CG
M3?K>S[^G/O\OV>0J75?H=C2T1=5?#1TM:DIEU-H? E2'J0Y*TBV-2OM[7B(9
M=[5N(CJV%ZIVP_5TW"%OQD,XNY*WM]=#*J?]>="5LEZ%*\5"95FHZDWX=3,^
MCN77=\A:*J8\ K2'9X[W>$QD#^GLF"&72_FXGT,9!Q1%5_+&8BLT<4)2/3U%
MS9OO*87B[2X8&%#&H\?U]'?[LVQ*>0<V80CF0L'K#"5[_GR;2J<=4 ^HJZO;
M0;$_\X8J7U<-YT,8G IS^\:47YI7:Y>KAN<,*%ET^\>VZ-L_^YXZVIMJ8:?1
MAAH4J/9G!+RUMW/NO7.6/O6^7_ODCISV?_$.^M^SCG?E:K/[&<>7/G">\,D>
M*Y;VZ*?GW:Q;;YBI[#8.>$][S\]U[S^?TJBV!DW<:;3[KDJXNKIL.53U.N!M
M\7,^<-I1T3#-H9\,SPPA[Z\OO5WWWO5,% RX)_5O=W[^?Y@_N+=W0',>7ZR^
MWIR.?_M!^OCGCG..4BFRNO\_L_7+BV[SB3/=E9$7O%S(%\)/&/5@\=Q.+5O0
MJ;YL2>=>_#\Z[)C=O?;P=V/CQ_DV->#]\(D_5]DGZYP:*GC7-T0S%;RKOQV&
MY74"WAK?K7W]_7K-"6_3W 7+W$$DHK/D1H]NT9F?_Y2.._;HS6[][Z^^7E\\
M\VR?I9<,?94*KAAYX<'[Z7O?_JK&CN[8Z/IR'IKE]W^X3E=>?:T>?6R6NONR
MZNOI<R?O#W;^Q-F8R:BEJ4D[.^ ]]F6'ZTUO?*W&=+1O=+WK>T)WMP/./UZK
MO_[C5L]!^X0Z5_3XC!P/,>-VA+-R0AC;Y#E$)FPW5H<<N+]>>>Q1>NE+UCTD
MP9JO<?&EE^GL<\Y3UG^D8CXR&X9<_,<-O]/T':>M^=3-OOV_9]VF._^YP&=K
M-NFRGQT=S6MRE8=<_I^W[**Y\[MT[=^>UM&';:]]]QC][+K7%?"&!Q<NZM>E
MOWQ4!Q\T5D<>,5E_N>EIST60T.$OG*3?7_.89C[>:>\VA\<[.>3>] #IV1?F
MRO,6(!!YWH1;MH):#GC#%H60-];DH'87![QS7,D[SWW-IOPWZ@^4#H.3+3LJ
MUC!FRVQ8"H$M%* _VS2X?&>7YO[D<BW[S34^:%96GRL?XM$GJS67+VNT/Q^U
M?^A$37C'ZY3<0, ;EBPYV)UYZ25ZXA>_C.8WZW/HN[ZO?P2\:UIS&X&U!:H'
M$ EXU[;A'@00J"\!^K-:V%]K!KPA((CKVENOU_=__@.5,AZ^.>/@UG/IQO.N
MWAT]1@57Z+;&FS2Q/Z76=).6-Q35Y?+=9E?ZIEPIEO!QK92?$P+><#W,Q]O@
M<-<Q@8H^[I7T,,>9AGX'L:Z6=;"2[V]2KJ_1K^%*WW2_ATCN\K&QT Z'L@YQ
MXRF'K,D6=2YM4G]OFT.99A^O"T,L+]1X3YW9[Z%(ERZ->[0YS[_KD#;9X'5Z
MV.62 V(?'O0Q1P_-7,I'04[XC%MP16]4O>L3#WL<.(?Y?U.N,LX[U"G%'3R'
M XO+73&\R&U8XF@[$:J4&UTA=Y[&M!+PUL*[MA;;4.W/"'AK;^_<\K>9^LJG
MKW;_,>"1"=ZA%[YX^CH;>=?M3^B+I_W.0S3WK7N(YB&JX#WUI$MT[RU/:-\#
M=M!YE[W+W\W=7/==JU]"7AMZ[U4%7>%)X;+JFW;9Q^]" =CJ2X;O]XL7=^G;
M7_Z3;OS#@WKQ,3OKLV>_3E.G50JU*NOPH ;NJZ-$./2'7D$(>),^@>?&ZQ[0
M]\_^BYZ9O4SO__C1^O G7^ZF^:0=]_4;NVQ*P/OP@QZB^<2?2P.5@/>-!+P;
M8QVVCQ/PUOBN[>WMU3XO.$;/N'HUYN$&_"E+I8&<WG3"JW3^=[^V6>%I;F#
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MEZ]'XM->E1][_?J#12<!/2!2=+(,VE"X5UJ^'F3"8FP&Y[;KD'KU>0.\)30
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M$+E_'V(X5]5M0UM9.W[M9^V[;EVM[K6DPZ&AO1V:D1;;MK27MJK^_264@-:
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M(%)T<GT1 %X#>L<94F>:>'X/0QM&VV:$()N.$[(H%FIH0^I?*5F,S,OF(M:
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M4;=N70+5#1@=7(4+C\?_1K3C^K_^KM=GC_\%",A[9^@$9-SV0SPCKIYFZ24
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MFK;MAK,T:!LS-T8&(S,ZD.9XY>(YC';*\_:1"-Y*M0CPQL1S<4FO.N:0>QX
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M&T[9\EZ]D0.Z: 3J$##_EC7!6P<)OVOR^TF)9A*\GY#@#1&"=_(U*G]M?2U
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M;3JC>@]7-O7%%U^A>D,BKKGF*D8MQZG<O3_\,%D1PR(OW:^?(?]C8J&?=T1
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M\6R,U4GB5-JLOR8Y;HQ5+JVE.,KY.ROU!&^:4F_AKT3;"=[G2?"29-?EX$)
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MO5OW<1,O7,3#S]^&+DF11J[T1NTJ!Z Z7K?N11,MZ4,'$@*:X#V0[J:^%HV
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M,;XSC'RNJ$;W_O%XYM5S$!$5(O0P:6Q-Y'IB=3"^U@3OP7C7]35K!#0"[8J
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M[^!DO@YOM^O3#6D$.A(!;<\Z$EW=MD9 (["G$3 W$#7!NZ>1U_UI!#0"[8V
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M2);"$I)=C];-J]:S&'E[K!IDA("7!.C/O 3-:1! P"L"UL,65T])O%("3H(
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M'V9_1H#7$<U))1! ((T%"/"F<0-P>@00\'\! B+^WX;4  $$;@K0GW$E(("
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M(\#KD :E&@@@D*8"!'C3E)^3(X" $P0(B#BA%:D# @AH ?HSK@,$$'"2@/D
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MYB^8*)FRA*JR1:CC=5!7!7NOJQ&]FEH1*#8^#A(P^S,"O YJ5*J"  )I)D"
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M>O6,;_Y   $$_%6 _LQ?6XYR(X! ; 'ZL]@BK". @+\*T)_Y:\M1;@00B"U
M?Q9;A'4$$$# ?0$"O.[;<20""""   ((((   @@@@  """"   ((((   @@@
M@  """#@50$"O%[EYF0(((   @@@@  """"   ((((   @@@@  """"   ((
M((" ^P($>-VWXT@$$$   0000  !!!!   $$$$   0000  !!!!   $$$$#
MJP($>+W*S<D00  !!!!   $$$$   0000  !!!!   $$$$   0000  !]P4(
M\+IOQY$(((   @@@@  """"   ((((   @@@@  """"   ((((" 5P4(\'J5
MFY,A@  """"   ((((   @@@@  """"   ((((   @@@@  "[@L0X'7?CB,1
M0  !!!!   $$$$   0000  !!!!   $$$$   0000  !KPH0X/4J-R=#  $$
M$$   0000  !!!!   $$$$   0000  !!!!   $$W!<@P.N^'4<B@  """"
M  ((((   @@@@  """"   ((((   @@@@  "7A4@P.M5;DZ&  ((((   @@@
M@  """"   ((((   @@@@  """"   ((N"] @-=].XY$  $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$O"I @->KW)P, 0000  !!!!   $$$$
M 0000  !!!!   $$$$   000<%^  *_[=AR)  ((((   @@@@  """"   ((
M((   @@@@  """"   ((>%4@S0.\14,?\FJ%.1D""""   ((((   @@@@  "
M"""   ((((   @@@@  """#@CL W/PZ56G4KNW.HQXXAP.LQ2C)"  $$$$
M 0000  !!!!   $$$$   0000  !!!!   $G"Q#@5:W+"%XG7^+4#0$$$$
M 0000  !!!!   $$$$   0000  !!!!   'G"!#@56U)@-<Y%S0U00 !!!!
M  $$$$   0000  !!!!   $$$$   0000,#) @1X5>L2X'7R)4[=$$   000
M0  !!!!   $$$$   0000  !!!!   $$$'".  %>U98$>)US05,3!!!   $$
M$$   0000  !!!!   $$$$   0000  !!)PL0(!7M2X!7B=?XM0- 0000  !
M!!!   $$$$   0000  !!!!   $$$$   ><($.!5;4F USD7-#5!  $$$$
M 0000  !!!!   $$$$   0000  !!!! P,D"!'A5ZQ+@=?(E3MT00  !!!!
M  $$$$   0000  !!!!   $$$$   000<(X  5[5EBD)\ 8'IY,2I0I)J7+%
M)$.&]++OW\.R9^=A";L6'N]5DB-75LE?*+>Q_=SIBW+ZY/EX]XVY(6NV3')[
MZ2)2Z+:\DB5+)CEY_*SLV+Q?SJH\8G_2I;M9KC(5BDMH:(CLVG90]NX\)-'1
MUVV[ZO+?7KJPRC.?Y,V74ZY<N2:[M_\G^W<?M>U76&T/"0VVI<5<N:[R/7SP
M9,PDEA%   $$$$   0000  !!!!   $$$$   0000  !!!! P,,"!'@5J+L!
MWC8O/RQ]!KTDV;)GMC7+]>O79=JX)3*X]U2Y>B7,MDVO?#:SISS>LIZ1_L/B
M=?)BBP^-Y83^&#.CASSZU ,2'&P/LD9%1<M7DY=)G\YC19]7?RI5*R439O>1
M8B4*VK(\?O2TO-QJ@&Q:O]-(?[+-@S+PDS?BE%]O_'/]#NG<?J@<W'O,V'?M
MOU.E^.V%C&57?YP^>4ZJ%&GM:A-I"""   ((((   @@@@  """"   ((((
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MQN_(NM6;;0'>$?V^D"F?+;;VT0N1$5$NIZ.V[<0* @@@@  """"   ((((
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M(O4>JBXKEJRWO6NX:Y]GY>T/GK?V>Z!"!]GW[Q%KG04$$$   0000  !!!!
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M*ED"O*EU>9$O @@@@  """"   ((((   @@@@  """"   ((((   @AX4H
MK](DP.O)2XJ\$$   0000  !!!!   $$$$   0000  !!!!   $$$$ @M00(
M\"I9 KRI=7F1+P((((   @@@@  """"   ((((   @@@@  """"   ((>%*
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M(""2'"WV10 !7Q:@/_/EUJ%L"""07 'S 2+WG,F58W\$$/ U ?HS7VL1RH,
M NX*F/T9 5YW!3D. 01\18  KVH);K9]Y7*D' @@X*X  1%WY3@. 01\38#^
MS-=:A/(@@$!*!,P'B-QSID218Q% P!<$Z,]\H14H P((>$+ [,\(\'I"DSP0
M0" M!0CP*GUNMM/R$N3<""#@"0$"(IY0) \$$/ % ?HS7V@%RH   IX2,!\@
M<L_I*5'R00"!M!*@/TLK><Z+  *>%C#[,P*\GI8E/P00\+8  5XESLVVMR\[
MSH<  IX6("#B:5'R0P"!M!*@/TLK><Z+  *I(6 ^0.2>,S5TR1,!!+PI0'_F
M36W.A0 "J2E@]F<$>%-3F;P10, ; @1XE3(WV]ZXU#@' @BDI@ !D=34)6\$
M$/"F /V9-[4Y%P((I+: ^0"1>\[4EB9_!!!(;0'ZL]06)G\$$/"6@-F?$>#U
MECCG00"!U!(@P*MDN=E.K<N+?!% P%L"!$2\)<UY$$ @M07HSU);F/P10,";
M N8#1.XYO:G.N1! (#4$Z,]20Y4\$4 @+03,_HP ;UKH<TX$$/"D  %>I<G-
MMB<O*?)" (&T$" @DA;JG!,!!%)#@/XL-53)$P$$TDK ?(#(/6=:M0#G10 !
M3PG0GWE*DGP00""M!<S^C !O6K<$YT< @90*$.!5@MQLI_0RXG@$$$AK 0(B
M:=T"G!\!!#PE0'_F*4GR00 !7Q P'R!RS^D+K4$9$$ @)0+T9RG1XU@$$/ E
M ;,_(\#K2ZU"61! P!T! KQ*C9MM=RX=CD$  5\2("#B2ZU!61! ("4"]&<I
MT>-8!!#P-0'S 2+WG+[6,I0' 022*T!_EEPQ]D<  5\5,/LS KR^VD*4"P$$
MDBI @%=)<;.=U,N%_1! P%<%"(CX:LM0+@002*X _5ERQ=@? 01\6<!\@,@]
MIR^W$F5# (&D"-"?)46)?1! P!\$S/Z, *\_M!9E1 "!A 0(\"H=;K83ND38
MA@ "_B! 0,0?6HDR(H! 4@3HSY*BQ#X((. O N8#1.XY_:7%*"<"",0G0'\6
MGPSI""#@;P)F?T: U]]:CO(B@$!L 0*\2H2;[=B7!>L((.!O @1$_*W%*"\"
M",0G0'\6GPSI""#@CP+F T3N.?VQ]2@S @C$%* _BZG!,@((^+. V9\1X/7G
M5J3L"""@!0CP*@1NMOG+@  "_BY 0,2W6[!JQ]OEKTG[?;N0E X!'Q&@/_.1
MAJ 8""#@$0'S 2+WG![A)!,$$$A# ?JS-,3GU @@X%$!LS\CP.M15C)# ($T
M$"# J]"YV4Z#*X]3(H" 1P4(B'B4TZ.9Y:N00YI_<:\L?'Z]G-IVP:-YDQD"
M3A2@/W-BJU(G! )7P'R R#UGX%X#U!P!IPC0GSFE):D' @B8_1D!7JX%!!#P
M=P$"O*H%N=GV]\N8\B.   $1W[T&&H^L*L7KYI>#:T[*#V_]Y;L%I60(^(B
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MWK>]R6%\=VH]0(T$_]66IJ>F#E5M%-_GT/X38EK'MX^WTLT'B-QS>DN<\R"
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MS D'=LT,DAO@7;-MDC'=LWE\4KY']O]21GXX,]%=4[M=[F]8168O&VPK1\P
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ME/H/W6.EQWXUFK4AQD+, &^,Y'@7+U^Z*DUJO"X'][I_;QIOYFSP"0&S/R/
MZ[HY?*7O<5TZD9@!WOCVB9FNG^$_^T@O^?7'6\^'DAK@C9E/?,NQ^ZO&C]\K
M4^;VC6]WE^E[=AV2>A5O33VO=Z*_<TE%8BP! KP*A)OM6%=% *XF]V8Y+"Q"
M/GA[G,S\?)FEY2MY6 5B(: $"(CX=G,7+))'NO1J;2ODO)DKU:\,=]C2 FE%
M_TI\R_$YMBK/F/BM-26.;4,25U[O\;2\.^#6K[?UM%^WI7\XB4>SFZ\(T)^E
M74OHD0M]AG24S%DR6(70KZ,8\MYT:UTOU&E459HVO\^6MF#V3_+[+UMM:7U'
M=I(,&6[]<GK_WJ/R^<CYMGW<7=']JOG1,_S%GFK/W.:/WR5*%9).75O$*?J,
MB=_)MK_=>QU)G,Q(\)J ^0"1>TZOD:?*B7SUM4()5=;5/6M"^[,-@<0$Z,\2
M$_+\=E_H>W2MO!W@_>.W[=*J<0\)#XNTH>I_(_VR?8HUVO;JE3#U3LTV<O'"
M%=M^L5>2$^#5H^LZMQ\BW\[]-78VK#M(P.S/"/"Z;E1?Z7M<ER[Y =Z!O2;)
MN&%S;=EY*L#KJK_R1("7_L[67*PD($" 5^%PLYW %1(@FZK<4U:6KHU_ZI6(
MB$@Y<>R,,36,[K@GCIHO)X^?L^GX2AZV0K$2, ($1'R[J5W] ,35/S!]NQ:>
M+1T!7L]Z.BDW^K.T:TW]?K*M)^=*MNR9K4+H'TI4S/^T7%!3V)F?\;-[2[,6
M=<Q5XWO6U.^E^\NCK+3B=Q22M3NG6NMZ(>:T5[8-R5RI7KN<+%SSL>VHAVN^
M(5O^C[W[ ).:Z.,X_J<70:4W05&*TD&0#M)%I-CH HJ !06D-Q4%1$3I307I
M':0(2!$1I:CP4E00%) J151$:5+>3,X)FV/W[O9NLYN]_>[SO'<ID\GL9\*\
M)K]+\K^?;<O"=:;/6\_("]T:W]3\.5-62;=V]N]]4R$6N$Y 7T#DG--U71-V
M#0K$^6;8?6D:["H!QC-7=4=0&S/L@R[2M$T=:Y_>'HNLGLXT?>E JXR:>+1:
M5_GVJQ_,9>H=X1V[-Y8*U4I(ZM0I;>7TC*KWW3>FRY(Y7]C>T:O7O_I..VG?
M^<8?P<7U#X35NW75(U<??K2BW'EW3EV=[;=Z=/,BXQ&N[PZ8(<>/G+:M8R;Q
M">CQC( W//M6_;'O2[V:2NWZY21'KBP^O\07J[?*\,&S9.O&W3>5^6332"E1
MIJ"U_*MU.Z1IG5[F?$+'*V_O +9VY&-BU[9]\G"Y&^\Q9[SS <7BFP0(> T2
M3K9O.BY8@  "829 (.+N#B/@O;E_O 6\T]__1'J_..;FPG%<PAV\<81R>3'&
ML]!VT*0%_:5.0_O=N9[O3U-W^7Y_<I[<EB&]K:'J76H5"SQM+7O\J1HR<G)W
M:UY-C!@TXZ;W"MD*Q'&F;)4BLO"S8;;2]2MUDNU?[[4M"\<9=0'RFX/3O+Z'
M3CTNL$2N9G+QPJ5P_&H1VV9] 9%SSH@]!/CB""0: <:S1-.5?G\1]4> *3S>
M9WGUZE7S_;M^5V1LD#Q%,B-DS2XY[L@B:=.E-JLX?OBT^3CD<W^=]UEEZC2I
M9-OAF7+;[>FL,C5*=I"]WQ^RYN,RD3'SK9(W?RZY]?9;)$W:5'+VC[_E\($3
M<LQH@WJ,*Y_($-#C&0%O^/=WYJRWB_KCXMLSII-4QA^/J''DV*%3<LSX0XU+
M%RXGZ O&=[Q*T$Z-C1GO$BH86=L3\!K]S<EV9!WT?%L$$J, @8B[>S70 6^J
MU"EN>ER5NP6\MZYPB;MM%PJ.'#PA9TZ?]5XX#DL)>.. % 9%(F4\<^MCKUH]
M7T\&CWK)=J0,'SC#O)M!+2Q6.K^LV#S:ME[/E+VGE7%Q[)0Y^_:$3M*BK?T1
MZ8]5[W;38YSUMO[\3FC J][]?>7?JU[O#/&G'4Z4K5*[E,Q:/MAGU1U;#9'%
ML]?[7,\*]PGH"XB<<[JO;V@1 @CX)\!XYI\7I0,KT/S9AV3H^,Y6I5LV[)(G
M:O2PYIE P!\!/9X1\/JC1ME@"3#>!4LZ<>R'@-?H1TZV$\?!S+= ()(%(B40
M"=<^3FC J_[*^.7>S:1XZ0*2KV!N47>_JO<,[=][1'9_=U!&OS5;CAI_H:@_
M[;H\*B4]'C7SS]\7;8].5>_RZ/%&:UU<KEZ])EV>>=<,/-1"%;R^V,/^>-!W
M7ILF!W\Z;FWC:V+(^)?EUMMN/-YU[M0ULFW3;E%W\Y4H75 R9$PO$X8OE"U?
M?"?>RGZQ:IM5M;I34+V[I&FKVI+GGIR2*W<6\Z^L3YWXW7QD_D\_'I;/5GXC
M*Q9N-(.:V +>Y[H]+L5*Y;?J5Q-+YGTAJQ9OMBUC)K0"D3*>U1Q60O)6RY9@
M[(.?GY2UW78DN!Y=0=[\.<UWF^EY]?O+M=ND6=V^YJ+H_\X\RW5N.TP63%MK
M+OK\N_<E_[UYK-7__'U!"F=]PAIGU%]9MWVID10JFE>RYL@HF3+?9MQ)D4XN
M7[XBO__VI_%.W=]EY9*O9.&,=>:_=UU1U]=:2K4Z96R/TU+KMFW98_R5]DFS
MV(%]1VUW"JOWKG7H\IB4KUQ4[C':E"-79G,_APX<E[T_'))1QABZ9]=!O0OS
MM[?QR==8ID+OYUZY\;A 5<$;W3^PM=M6>0PSHZ;UD,>:5?=98L.:;=+\X:B^
M\%F(%:X2T!<0.>=T5;?0& 00B(< XUD\T-@D8 *??CM&BI3(9]77H=E WI-K
M:3#AKX >SPAX_96C?# $&.^"H9QX]D' :_0E)]N)YX#FFR 0J0*1$HB$:_\F
M).!MV+2J#!K9T7C<C/UQJ)X6%\Y?E+?Z39;)HY>:BT=.[2Z/-Z_A643*YV\M
M1WZ)"C\Z]FHLO=Y\QK;^R5H]9//Z7>:RSOV:2;?7;@3 :F'MTB_([IT';-MX
MFSGPSS))Z?'X+O7.S>Q&F)+3> 27_KS\]%!99(0VT<L.&S!51@R<;193[U29
MOFR@W&>$/[%]"F5^W R\HP=/ZMVAN5-&W4'8H$E5&3>CMZVJ\_]<E$<??$5^
MV!'[][)MR(RC I$RGKDUX%6=NV7_5+DCSXWP63WF2OT[4_^FYJX>(A6-=Z=Y
M^\R?OL;\8Q%OCV!?NWR+M&GTNK790X]6D _GO6K-^YJX?/E?:6*\"TF_OVW=
MKHE2X+X[?14WE^_;<TBJ%^M@3JOW'PV=T%GRW)7=YS;J,8-#^G\DX]]98)6)
M/C[%-)8U;E-+WON@J[6MFFADC"W>WO5D*Q1M)EWZ-++CV!SSD5S15EFSZM&!
M9?(^903@9ZQE3+A;0%] Y)S3W?U$ZQ! ('8!QK/8C2CAG(#Z[ZVLV3.8.U#_
M33IAV$+S#Y6=VR,U)V8!/9X1\";F7@[?[\9X%[Y]%XJ6$_ :ZIQLA^+08Y\(
M(!!(@4@)1 )I%LRZXAOP%BA\IWSZS1A;8!I3NQO7[B&;/M\E]9ZH+!-GV^_P
MZO+L,)D_->K.NF4;1TC)!^ZU537AO04RL.>'YK+9GPZ6RC5*6>N/'#HAY?.U
ML>9CFH@>BG@K&Y> =_&&]Z1T^4+>-K]I66P!KW+\9.-(27M+U#N>5 7JHD"[
M)F_*IQ]ONJD^%H16(%+&,S<'O$,G=I+FS]@?KZS><79H_PGYX?0"294JA=>#
MY-B14U+V[E92JT$Y^6CAZ[8RK[XRSOHC%+4BK@&O*GORUS-R?YX6:E+\"7AS
MY<DJ:[=/D/2WWGBJ@%F)EQ\JY'WH@8[6G;S^C&6!"GB]U;-@YEIYHD5-6XL'
M]?G0%D;;5C+C.@%] 9%S3M=U#0U"  $_!1C/_ 2C. ((N%9 CV<$O*[M(AJ&
M  )Q%"#@-: XV8[CT4(Q!!!PK4"D!"*N[8!8&A;?@-=;R+ELP099O6RS>0==
MTS9U;'L^^/,QJ5JXG1%DII)=)^;9@N%YTU;+*VW?,Q^%NNW03%&//_;\J,<=
M5RO:7I*G2"9[?EMH/ KY1A@Z:<QB>:W+!,_B/J?]"46BE]5W\*I'MV[\\2/;
M/E1P-+C/)/G[W'FYRWA<<[7:I>5!XS&MZA-3P*O6+=\R2N[.?X>MOB'])\N8
M(?-LRYAQAT"DC&?)4B>5I,GM_P[CTP/7KER7JQ>OQ6=3G]L\\F1EF3#+_D<B
M/9X?(4<.G939*][RN9U:4?'>IZ5ENX?E^:Y/VLI5*]9.?MISQ%I6LWY9F;)H
M@/RP<[^L7[U5?OKQB"1+EE3N*7"'//E43<F2+:-55DWHIQ"T?N$1J?'0 U*]
M[@.V]6N,<?'@_JC'R!\Z^*M,'?>)S/CD36N<4(7/_OFW#.@^479NW2<5'BPN
MKP_K8.PSF57/DGGKY<460\SYZ..35<AC0O^QBK=@-CYW\"[X;*B4JU+,VH-J
M;_E\K>7;7V;(+>G26,OW[CXD-8I'W:&L%Y:I5%A2&..WK\^1@R>MISCX*L-R
M9P3T!43..9WQI58$$ B> .-9\*S9$P((."N@QS,"7F>=J1T!!)P7(. UC#G9
M=OY 8P\((."L0*0$(LXJ.E=[? )>=3'_Q]\7V8)8]8C0!I6Z6 V=.+>OU'NL
MLC6O)JH4;BL']AV[*=C0=^&V:%]7WA[;R;:-GJE0L(UDSGJ[+/URA%YD_M9W
M!ML6^IB)'HK\^?LY6;]FJ_'^WF-RS7C7;W;C4<U3QBTU[Y*+7E8'O$7OSR<K
MMXRQ[>'78Z=EVL1/9)/Q&&GUKDSU>&55[L':]\O8M^>+>FQI]$<TJPI6+=DH
M=1I6M-6U<-9GTJGU.[9ES+A'(%+&,S<'O.H1R[M^G6L;?]0?B9PY?=86W"Z=
MOU[*5"ALO-/VQB/8NS\W7)JV>4CN+W>?=5"=./Z;E+ZSI36O)M0?F63(E-YX
MW^Y?YMWU^0OED5QYLDA&XUV\*L"M]4@Y6_DF=7K*QG4[S65EJQ21A9\-LZVO
M7ZF3;/]ZK[5,O7=WWQ\?VP+<+XP@>6#O25:9:4O?L+5]C_%.\UJEGC?71Q^?
M8AK+U#O&1T[N;M6K)AI4[BS_V_*C;5E,,[GORB:;]DVQF<^9LDJZM1LNWM[+
M6[=<1_ENV\]FE3F-]Y-_<V!Z3-7+\D5?2H<F@V(LPTIG!/0%1,XYG?&E5@00
M")X XUGPK-D3 @@X*Z#',P)>9YVI'0$$G!<@X#6,.=EV_D!C#P@@X*Q I 0B
MSBHZ5WM\ MY2Y>Z]*6CMUWFL3!F[S&IHG4;E9=+\UZQY-='VR0&R:O%F>>JY
M>O+6Z)=H^&,N   ICDE$051LZ\K>TTJ&C.THU8SPQ-NG?Y=QQIV[J:3/H+;6
MZK-_G)-B.9K$^?U&T4,1'=I:%7I,^"JK[N+;=GBF$39'O6/)8Q-S4H6YNW<=
MD!&#9]D>L>PMX(V^[8&?CDK-DL_)Y4M7HJ]BWB4"D3*>N?D1S>I06/'U:"E6
M*K]U5.S?=U34^[Z+E,AG+>O6X3TSX&W2^L;3!%8NWB@UZY4U[B9-;I733Q"P
M%OPWH8+:SGV:2_FJQ25Y<M]WGZKB31_J)5]]ML/<,BX!;\FR!6795R/_VU/<
M?EV\>%GRI6]@%O8U/GFK*47*Y)(G[XUW%JLR^_<>\U;4YS)O[SYO7J^/;%C]
M/]%W.WMN[/ED!0)>3QGW3>L+B)QSNJ]O:!$""/@GP'CFGQ>E$4# O0)Z/"/@
M=6\?T3($$(B;  &OX<3)=MP.%DHA@(![!2(E$'%O#\3<LO@$O V:5)5Q,WK;
M*F[?]$U9L7"CM<Q;@-&QU1!9/'N]9,^52;;^,M,JJR940/SJT/;6HYO5G:P-
M&S]H!2L;UFR3*U>NVAY]ZN_=KOZ$(C&5'3#\.6G;L9&M_=YF-JW?*8UK]317
MQ27@58]ZKEZL@_SS]P5OU;',!0*1,IZY/>#M/:B-O-BC:8Q'A/JC$?7'*.-G
M]HFQG!Z7/ L]W;'!38](]EP??=K?@-?;&!J]3F_S^KP@IO')VW8)7?;5CY/-
MQ\][UJ.>VG#ERC5CS$XN)<H4]%QEW/E\5DKE:2Y7_KTJ!+PV&M?-Z N(^MAR
M70-I$ (((!!' <:S.$)1# $$7"^@QS,"7M=W%0U$ (%8! AX#2!.MF,Y2EB-
M  *N%XB40,3U'>&C@?$)>"O5*"%S/HUZ%Z2N5K_O4<]7K%Y<YJYZ6\^:O[L\
M.TSF3UUK3J\PWCU;[/X"UGIU]YWGNW5;/-)7GG_E2:E4O819YNK5JY(T:5+;
M(T*CA\I693XF_ E%8BJ;.DTJ42&O>A=GRI0I?.PM:O&CU;K*MU_]X/41S=XV
MG#5YI?3HX-^=?=[J89DS I$RGKD]X/4VOGCVN'KG=^7[VAJ/6;Y5=AZ?8XX=
MGNL]ITOD:BJ_G?K36J3N>/WAU +ST<S60F-BZ^;=LN/;O9(R50IIU>$1SU5^
MW\%;J:8QAJZTCZ&G3IPQ]K''5J_GS'ECC.S<)NK1SS&-3Y[;!&*Z=(7[9/$7
MP_VNZNG'7Y<U2[>8[TYO_NQ#UA_K>*MHM_%H^RU??.=M%<L<%M 7$#GG=!B:
MZA% P'$!QC/'B=D! @@$24"/9P2\00)G-P@@X)@  :]!R\FV8\<7%2. 0) $
M(B40"1)GP'<3GX W6\Y,LNV0_0Y<_3Y&W< N_9I+U]=:Z5GS=[T*+\O.;_>9
MT]X>^:D+JW?8%LGVA#S5H9X,>#?JG9-ZG?Y]Z=*_4C3;D^;[;O6RV'[[$XKX
M*GM;AG12JWXY63IWO=R2+JU4J572>%1L 2E:,I^4J5C8]NA7U9XA_2?+F"'S
MO :\X]^=;P9%ZIW&GI^G&O23SU=N]5S$M$L$(F4\*]'V;LE6]/8$JY_\[D_9
M,>E @NN)7D&JU"G,$%;]L86WS]0)RZ3O2V/-5<LWCY+BI6_\,8EG><_WVNKE
MY1\L)O/7#-6SYN_!?2?)N*'SS6GU/M[/=[YO6Q_;';Q-ZQJ/<%Z[P]I&O4]\
MQ[$YUKR:6#!SK17@VE88,Z4K%C(#4AV"^AJ?HF^GYE68_-K0#M:JZ]>O2X>F
M XUWCQ^WEL4T,63<2]*R7;V8BGA=M^+CKZ1]XX%>U['0/0+Z B+GG.[I$UJ"
M  +Q$V \BY\;6R& @/L$]'A&P.N^OJ%%""#@GP !K^'%R;9_!PVE$4# ?0*1
M$HBX3SYN+?(6\!X]?%)V[]COM8+#OYR4U[M.E.U'9TF6;!FM,I<O_RN=GGY'
M5GZ\451 \OZ<_I+^UK36>O7^2!7(7CA_R5QV7[&\LF;;>&N]YX1Z3V:[)]\T
MWAN973;MF^*YRII>M_(;:=7@56L^+A/^A"*^RE:I74IF+1\L1PZ=D ]'?6Q\
MWTUR_,AI<_>/M:@NHZ;TL#5E^, 9\NZ &3<%O"IDR9VRKK1^X1$9-+*C;9L3
MQW^3&L6?D[-__FU;SDSH!1C/0M\'N@4SEP^4JK5+ZUG;[V<;OV&] [O'&ZWD
MY=[-;>OUS,3A"^7-'A_H6?-WHV8/RIAIO6S+WG[U(QG]UESSCN!^;[<5S_?Z
MJH)-ZO24C>MVFML4+95/5GX]QK:]&M->>V6"9,N9450HO7G]+OGZP#3)E3NK
MK=RBV>MD\I@E<OC KY+)"($+%[];&C]5R_A#DOM%/1*Y0:4N9GE?XY.MLO]F
M&K>I)>]]T-6VJM&#K\C6C;MMR[S-J"!]^]$Y<NMMMUBK_SYWWGC/^$%K7D\4
M*7&/[:YG]?\)I7(WES]_/Z>+\-N% OH"(N><+NP<FH0  GX),)[YQ45A!!!P
ML8 >SPAX7=Q)- T!!.(D0,!K,'&R':=CA4(((.!B 0(1%W>.T31O 6],+5;!
M9OE\;<1;F!G3=F_UFR1CWXZZ TZ7V_SS%,E]9W8]:_WNVOX]F?O1:G/^LYT3
MI6"A.ZUU>J+'\R-DUH>?ZMDX_?8G%/%55@>\GCM4@8=Z?'3:6U)[+C:GFSW<
M6[Y<L]UGP)LD21)9M'Z8E*E0V+:MO^\7MFW,C&,"C&>.T?I=<8>NCTO_(>UN
MVDX]SKUHML;RU]E_S'4/5"XBB]9%/=HX>F'U*/@O5FVS+2Y<XFY9]>TXVS(U
MHYX:D,IX/+.WC^<=O.H/6_:<6>2MF+ELWYY#YKNVJS]<1J8M>=-GN>@K0A'P
MUGNBLDR<W=?6E$EC%LMK72;8EJD9;W?Z]GEYM$P;O_RFLBQPCX"^@,@YIWOZ
MA)8@@$#\!!C/XN?&5@@@X#X!/9X1\+JO;V@1 @CX)T# :WAQLNW?04-I!!!P
MGP"!B/OZQ+-%\0UX51WC9_>6^D]4]:S.Z_26#;ND2>U><O7J-=MZ]1[;MAT;
MV9:I.UOOS]-<3IWXPUS>:V!KZ=BS68QE;"MCF/$5VGK;Q%=9;P&OM^W5,L_'
MQ+[8\TGI/;"M553?P:L6Y+OW#EEMW,T<_7V^GG<A6ALR$5(!QK.0\MMV7LBX
MNW7UUIN#6,\@5&V0/$4R^?[D?$F7_L83!=1R%=@6SO*$7+P0]50!M4Q]U!]=
MS%OSMI2O6BQJ01Q^>@:\JOCDA:]*[085O&ZI UZULMOK+:53GQ:V=XM[W<A8
MZ/F]?(U/WK9-R!V\4Y<,D!H/E[55V[!*%]GFY5W!WAYMO?V;'Z5^Q<ZV[9EQ
MEX"^@,@YI[OZA=8@@(#_ HQG_INQ!0((N%- CV<$O.[L'UJ%  )Q%R#@-:PX
MV8[[ 4-)!!!PIP"!B#O[1;>JQ ,%Y9.-(_5LK+_W[CYD/#[XQOL<&S:M*J\.
M;2_9<F2Z:=NS?YR3(:].D1D35X@*-*-_*E8O+G-7O6U;O'/K/JE7_F5KV?WE
M[Y,E&X9;\VK",^BPK8AE1H4\MV=,;Y4:T'V"?#!BL37O.>&K;(X[,DO/@6VD
M]B/E;8\M]=SVN^T_B[K+;<&TM=;B-B_6EX$C7K3FU5V_]V9\S)KW]DYBPA&+
MQS43C&>NZ0JS(3N.S9;,63/8&C5R\$QYY[7IMF7> M>-G^\P__#$5O"_F2S9
M,LC0\2\;[]LN;UNM'I\^>_*G1BC;W+QK7Z^L7ZF3;/]ZKYZ53%ENDQ>Z-Y:&
M3:I*]IR9K>5JXOL=/\M#96X\EET]KK['@-;F8YB]W2&L'G6\R6CKW&EK9-F\
M#69=OL8GVX[^F_%V%VZ=,B_(#SMB?S?RSN-SS>^BZU6/[R]W3VL]:_NM@O%M
MAV=(UNPW_K] /9J_<);'Y=+%?VUEF7&/@+Z R#FG>_J$EB" 0/P$&,_BY\96
M""#@/@$]GA'PNJ]O:!$""/@G0,!K>'&R[=]!0VD$$'"? (&(^_K$B19ERYE)
M[BF82[+GRBRG3_XA!_8>DV.'3SFQ*U?4J<*,+-DSF._4S)HCHQGVG#CVFYPX
M>L;\_JYH)(T(N #C6<!)75UAKCQ9)=]]N25Y\J3RJ_%O>X_Q[EEO?ZSBZTNH
M<4(%N&G3I99+%RZ;[Z,]8KS'W-M'E<V9.XO<E2^'I#,>\WSVC[_E-V,L/7;X
MM/7N<F_;L0R!A CH"XB<<R9$D6T10, - HQG;N@%VH   H$0T.,9 6\@-*D#
M 01"*4# :^ASLAW*0Y!](X! ( 0(1 *A2!T((. & <8S-_0";4  @4 )Z N(
MG',&2I1Z$$ @5 *,9Z&29[\((!!H 3V>$? &6I;Z$$ @V ($O(8X)]O!/NS8
M'P((!%J 0"30HM2'  *A$F \"Y4\^T4  2<$] 5$SCF=T*5.!! (I@#C63"U
MV1<""#@IH,<S EXGE:D; 02"(4# :RASLAV,0XU]((" DP($(D[J4C<"" 13
M@/$LF-KL"P$$G!;0%Q YYW1:FOH10,!I <8SIX6I'P$$@B6@QS,"WF")LQ\$
M$'!*@(#7D.5DVZG#BWH10"!8 @0BP9)F/P@@X+0 XYG3PM2/  +!%- 7$#GG
M#*8Z^T(  2<$&,^<4*5.!! (A8 >SPAX0Z'//A% () "!+R&)B?;@3RDJ L!
M!$(A0" 2"G7VB0 "3@@PGCFA2IT((! J 7T!D7/.4/4 ^T4 @4 ),)X%2I)Z
M$$ @U )Z/"/@#75/L'\$$$BH  &O(<C)=D(/([9' (%0"Q"(A+H'V#\"" 1*
M@/$L4)+4@P ";A#0%Q YYW1#;] &!!!(B #C64+TV!8!!-PDH,<S EXW]0IM
M00"!^ @0\!IJG&S'Y]!A&P00<), @8B;>H.V((! 0@08SQ*BQ[8((. V 7T!
MD7-.M_4,[4$  7\%&,_\%:,\ @BX54"/9P2\;NTAVH4  G$5(. UI#C9CNOA
M0CD$$'"K (&(6WN&=B& @+\"C&?^BE$> 03<+* O('+.Z>9>HFT((! 7 <:S
MN"A1!@$$PD% CV<$O.'06[01 01B$B#@-70XV8[I$&$= @B$@P"!2#CT$FU$
M (&X"#">Q46),@@@$"X"^@(BYYSATF.T$P$$? DPGOF283D""(2;@![/"'C#
MK>=H+P((1!<@X#5$.-F.?E@PCP "X29 (!)N/49[$4# EP#CF2\9EB. 0#@*
MZ N(G'.&8^_19@00\!1@///48!H!!,)90(]G!+SAW(NT'0$$E  !KX' R3;_
M&!! (-P%"$3"O0=I/P((: '&,RW!;P002 P"^@(BYYR)H3?Y#@A$M@#C663W
M/]\>@<0DH,<S M[$U*M\%P0B4X" U^AW3K8C\^#G6R.0F 0(1!)3;_)=$(AL
M <:SR.Y_OCT"B4U 7T#DG#.Q]2S?!X'($V \B[P^YQLCD%@%]'A&P)M8>YCO
MA4#D"!#P&GW-R7;D'/!\4P02JP"!2&+M6;X7 I$GP'@6>7W.-T8@,0OH"XB<
M<R;F7N:[(1 9 HQGD='/?$L$(D% CV<$O)'0VWQ'!!*W  &OT;^<;"?N@YQO
MAT D"!"(1$(O\QT1B P!QK/(Z&>^)0*1(J O('+.&2D]SO=$(/$*,)XEWK[E
MFR$0:0)Z/"/@C;2>Y_LBD/@$"'B-/N5D._$=V'PC!")-@$ DTGJ<[XM XA5@
M/$N\?<LW0R 2!?0%1,XY(['W^<X()"X!QK/$U9]\&P0B64"/9P2\D7P4\-T1
M2!P"!+Q&/W*RG3@.9KX% I$L0" 2R;W/=T<@<0DPGB6N_N3;(!#I OH"(N><
MD7XD\/T1"'\!QK/P[T.^ 0((1 GH\8R ER," 03"78" U^A!3K;#_3"F_0@@
M0"#",8   HE%@/$LL?0DWP,!!)2 OH#(.2?' P((A+L XUFX]R#M1P !+:#'
M,P)>+<)O!! (5P$"7J/G.-D.U\.7=B. @!8@$-$2_$8 @7 78#P+]QZD_0@@
MX"F@+R!RSNFIPC0""(2C .-9./8:;48  6\">CPCX/6FPS($$ @G 0)>H[<X
MV0ZG0Y:V(H" -P$"$6\J+$, @7 48#P+QUZCS0@@X$M 7T#DG-.7$,L10"!<
M!!C/PJ6G:"<"",0FH,<S M[8I%B/  )N%R#@-7J(DVVW'Z:T#P$$8A,@$(E-
MB/4((! N HQGX=)3M!,!!.(BH"\@<LX9%RW*((" FP48S]S<.[0- 03\$=#C
M&0&O/VJ410 !-PH0\!J]PLFV&P]-VH0  OX($(CXHT59!!!PLP#CF9M[A[8A
M@("_ OH"(N><_LI1'@$$W"; >.:V'J$]"" 07P$]GA'PQE>0[1! P"T"!+Q&
M3W"R[9;#D78@@$!\!0A$XBO'=@@@X#8!QC.W]0CM00"!A CH"XB<<R9$D6T1
M0, - HQG;N@%VH   H$0T.,9 6\@-*D# 01"*4# :^ASLAW*0Y!](X! ( 0(
M1 *A2!T((. & <8S-_0";4  @4 )Z N(G',&2I1Z$$ @5 *,9Z&29[\((!!H
M 3V>$? &6I;Z$$ @V ($O(8X)]O!/NS8'P((!%J 0"30HM2'  *A$F \"Y4\
M^T4  2<$] 5$SCF=T*5.!! (I@#C63"UV1<""#@IH,<S EXGE:D; 02"(4#
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M!!!(B #C64+TV!8!!-PDH,<S EXW]0IM00"!^ @0\!IJG&S'Y]!A&P00<),
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M!,)90(]G!+SAW(NT'0$$E$#$![SKUZ\7]3\^"""   ((((   @@@@  """"
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M*E66,V?.R%<;O[3*9<R840[_<LR:5Q.JW35J51-EH#\$O%J"WP@@@  """"
M  ((((   @@@@  """"   ((((   @@X+T# ZV? .WK,*.G=IZ?5,\L_^52J
M5JEJSI\X\:M4K5;%>(SR47.^=NTZLFC!8JMLA^?;R<R9,\SWYZI@^-RY<^:Z
MV +>\1/&2?Y\^47=@:L_#U:O(ENW?FO.5JQ0259]ND9Z&H]]'CMNC+FLLA':
MZD<G/_9$(UF].NJ1RD^W>49&CQHK7W^]1;88_^O0_CGST<QJHY&C1DC??KW-
M[=6/ _L/2=8L6<WYW\[\9MYY?/3H$<F1(Z?\^NMQ<SD!K\G #P000  !!!!
M  $$$$   0000  !!!!   $$$$   02"(D# ZV? V[CI$[)BQ7*S<QH8[[6=
M-7..K:,F3?Y0.G6.>K2Q>GSRR5]_,]]E._']"=*U6Q>S[(SIL^2=84-EY\X=
MYGQL :]M!__-='SI!?.]O&JV>?.6\OZ$#^31QQL:[\:->A_N&P/>E%>Z=#-+
M3Y@X7KIU?\6<KE"^HJQ>M=:<COYCW>?KI$'#>N;B].G3RY%#Q\T[E*]>O2H-
M&STBZMW!.7/FDJE3IDFMVC7,<@2\T1691P !!!!   $$$$   0000  !!!!
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M\N_ER]:[?O6*4Z=.29^^O<Q9%6Z/&CE&BA0I*D4*%]%%^(T  @@@@  """"
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M9\";-4M6.;#_T$UE6(   @@@@  """"   ((((   @@@@  """"   ((((
M H$7(."-9\"KN^+*E2LR=MP8,^Q5R_+DR2.?K]L@V;)FDX,'#TK>O'EU4=MO
M%;Y>NW;-7*;NJ$V2)(EM?4)G5+M^^ODG<Q\%\A>0%,:CF@/UN7[]NA4XJW:K
M]O-!  $$$$   0000  !!!!   $$$$   0000  !!!!   'G!0AX$QCPJBY2
M[](M4:J87+ITR>JQ=,8[>?_YYQ\Y=_:\M8P)!!!   $$$$   0000  !!!!
M  $$$$   0000  !!!! ("$"!+P!"'A5!\Q?,$]>Z=I9_OCC#ZL_U-VM!+P6
M!Q,(((   @@@@  """"   ((((   @@@@  """"   ((()!  0+>  6\JA_4
M';M[]NR6$R=/2-JTM\@=N>Z0 @4*)+"+V!P!!!!   $$$$   0000  !!!!
M  $$$$   0000  !!!"($B#@#6# RT&%  ((((   @@@@  """"   ((((
M @@@@  """"   ((."E P$O Z^3Q1=T(((   @@@@  """"   ((((   @@@
M@  """"   (((!!  0)> MX 'DY4A0 """"   ((((   @@@@  """"   ((
M((   @@@@  "3@H0\!+P.GE\43<""""   ((((   @@@@  """"   ((((
M @@@@  "" 10@("7@#> AQ-5(8   @@@@  """"   ((((   @@@@  """"
M  ((((" DP($O 2\3AY?U(T  @@@@  """"   ((((   @@@@  """"   ((
M((   @$4(. EX W@X415"""   ((((   @@@@  """"   ((((   @@@@  "
M""#@I  !+P&OD\<7=2.   ((((   @@@@  """"   ((((   @@@@  """"
M0  %"'@)> -X.%$5 @@@@  """"   ((((   @@@@  """"   ((((   @@X
M*4# 2\#KY/%%W0@@@  """"   ((((   @@@@  """"   ((((   @@@$$ !
M EX"W@ >3E2%  ((((   @@@@  """"   ((((   @@@@  """"   )."A#P
M$O Z>7Q1-P((((   @@@@  """"   ((((   @@@@  """"   ((!%" @)>
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MKY]P%$<  ?<)$/ 2\+KOJ*1%""#@KP"!B+]BE$<  ;<*,)ZYM6=H%P((Q$=
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M,E4C@$!0!!C/@L+,3A! ( @">CPCX T"-KM   %G!0AX"7B=/<*H'0$$@B%
M(!(,9?:!  +!$& \"X8R^T  @6 )Z N(!+S!$F<_""#@E #CF5.RU(L  L$6
MT.,9 6^PY=D? @@$7(" EX WX <5%2* 0- %"$2"3LX.$4# (0'&,X=@J18!
M!$(BH"\@$O"&A)^=(H!   48SP*(254((!!2 3V>$?"&M!O8.0((!$* @)>
M-Q#'$74@@$!H!0A$0NO/WA% (' "C&>!LZ0F!! (O8"^@$C &_J^H 4(() P
M <:SA/FQ-0((N$= CV<$O.[I$UJ"  +Q%'!!P/M_    __]?#_PP  !  $E$
M053L70?8%376CKV+K@4[HH"B:T=1403KV@MV716[:^\*J A6+&O%7E?%7@&Q
MKB*6M:P54;!A 12[V,O]\\;_S.;F9N9.[G?;S'W#\S%S,YGDY$WF)#GGY&2Z
M@@ZJ@>'[[WYJ8.DLF@@0 2+0=@2>>FJTVG3S3=2ZZ_94#XYXJ.T9,@<B0 2(
M0(,0(#]K$/ LE@@0@9H@,.?<LYE\IWW[8TWR9Z9$@ @0@7HA0'Y6+Z19#A$@
M K5&0/@9Y&>0HS$0 2) !#*+P'2:<JU=G77VF=4,,TS?D&I,1P5O0W!GH0$(
MN#8(TTV'+R<^U#I]?,E\TJH(4"'2JBW/>A.!_"% ?I:_-F6-B$ K(R "1"IX
M6[D7L.Y$(!\(D)_EHQU9"R) !)02?D8%+WL#$2 "F4> "EZEN(,W\]VXIA6X
M\ZX[U%Y]]R@J8Y999E%SSS6WZK;ZZNJH(X]6:ZVY=O0\-#U>7'6UE=3X">.C
M/*! GGWVV=6BBRRJMMEF.W7"\2>JF6>>.7K.&R+@(D"%B(L(?_L0^.FGG]3O
MO_^NYIAC#M_C*.ZKK[Y2;[_]EOKVVV]5AR675)V6[J2MP&:(GJ>]J58^:<MC
MNGP@0'Z6CW9L]EJ(,5XYH[VT]7C__??564/.4.NMNY[:==?=O:]5NTQO(8QL
M.@1$@$@%;],U3:8)$GXBE:@6+Y/\>"4"/@3(SWRH,,Y& +PIE!^Y_,S.#_=)
M^5UT\85J[)MOJ'/./D_-/??<YM6VY.>6S=_Y14#X&16\^6WCI)I-F3)9O?_!
M^^J''WY4'9;HH#IUZI24W/LLB=?X^-:T:=-,F5.G3E6++;J8ZMBQHYIIIIF\
M>=N1Y',V&KSW(D %+Q6\WH[!R B!.^Z\7?7=>T^UJ&:^*ZVTDOKCCS_43S_^
MJ,:.':NF?CY50=G[R$./J5577<V\$YH>+ZVRVHIJPH0)JG>OWFHVK=C]Y9=?
MU!=??*%>>>5EA0%CZZVV43??-"RBB3=$P$6 "A$7$?[V(=![@_74&V^\KJ9^
M^J7OL?KUUU]5O_XGJ*NNOE+]]MMO49K.G3NK<\_YI]I@_0VBN*2;:N635 :?
MY1<!\K/\MFVSU*S'NFNI5U]]Q0@,QXU]6RVVV.)M)NVDDP>H?UYPGKIMV!UJ
M\\VW*,FO%F66%,*(ID1 !(A4\#9E\V26*!H(9[;I,DTX^5FFFZ_FQ,M<"'*M
M!^X?F;J\SLLLK29/GA2;_MEGGE<K_'6%DN<P)N[4I:-:9IEEU3-CGHN>5YI?
ME %O6@(!X6=4\+9$<T>5O.""\]6EEUU:PG-66&%%=?&%EZANW5:/TB;=7'_#
M=>J00_\1FV3++;92PVZYS3Q_[;57U7'''ZN>?F:,D?'+2^W;+Z1.&W2:VF67
MW22JY$H^5P()(WP(4,%+!:^O7S#N?PB(PG:O/?NJ2RX>&CV HG>G7790#SXX
M4AU[S/'JE),'FF>AZ?&2*'@GO/VN6GCA14P^^.^EEUY4Z_5>5\TXXXQJ\B>?
MJ=EF^_,,KR@!;XC _R- A0B[0AP";X]_6[WYYEAU[[WWJ+ONOM/PD3@%+Y03
M6)AC<KN;WH&V\,(+JX<?>4C=?/--:M999U5//C%&+;_<\G%%1?'5RB?*D#<M
MA0#Y64LU=]TK.U;SP^YK=HO*Q?P-\[BV!!C$=%FVDU$8OSUN@IFWV?G5HDP[
M?]XW-P(B0*2"M[G;*6O4R?J1!L)9:[ELTTM^ENWVJR7U5U]SE3KBR,-,$;W6
MZZ6&/_!@ZN*6[MQ1??KI%+7N.NMZWQEZZ15FIYO[\/(K+E/'''N4.O^\"]3^
M^QT0/:XTOR@#WK0$ L+/J.!MB>:.*KGQ)ANJ9Y][1O74YRY#[C7;;+.K40\]
MJ%Y__34USSSSJ)?_^YI:8/X%HO1Q-]=>=XTZ[/!#C*%P1^WUS@T]>JRK!O0_
MR40/&W:SVN^ ?=522RVE>O181[6;NYUZ]-%'U%O::Q["/7?=IS;::&-S[_Y'
M/N<BPM]>!*C@I8+7VS$8&2$0I[!%@K/./D.==OI@=>()_57_?@/,.Z'I\9(L
MT%T%+Y3(\\XWMW'9\.$'GQBWS:80_D<$' 2H$'$ X<\(@3WVW%W=?<]=T6\8
MBO@4O/ :T'7Y+NKGGW]6K_SW]:)%]"Z[[J0>&'Z_=A??+YJD1ADZ-]7*Q\F6
M/UL( ?*S%FKL!E2UWX 3U4477:!VVG%G==OMMQIW7.!Y;0G@C^"31Q]UK#IU
MX*"2K&I19DDAC&A:!$2 2 5OTS91)@F+6S_20#B3S9D9HLG/,M-4=244FQZP
M^6'..><T1_Q4JN#][IL?$MTQNY5:JT=W[0EOO'IWP@>J7;MVT6-1\(;F%V7
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MSF?*E,GF2)^GQSRG9IYY9@/N3COOH$:,'*YFF646A?2^<.@AAZO>O7J3S_G
M85QY!*C@I8*W?"]A"B) !)H= 2I$FKV%&D<?#%1@>.(+N^ZZN[KR\JNB1Y]J
MBT+LUATV[.8H#C=__>L*6HE[KM[!V[,H'DJ3CS[Z4)U[SOGJP ,.BIZ%YA.]
MR!LBH!$@/V,WJ"8"3XT9K3;=;!.U^NIK*)\K92D+NW&Q*_=0;0!SYAEG2[3W
M"D.87NOW--X++KEX:$F:6I194@@C,H. "!"IX,U,DV6"4!H(9Z*9<D<D^5GN
MFK2J%9+C*6!X<O]](TKR]JT='__WXZI?O^/-6;OV"S X'G+V.6J;K;>-HK?M
ML[4YNW+<V+<5/.SY0DA^OO<9USH("#^C@K=UVAP>,@\][& UZJ$'U8\__EA4
M<<C&!I\ZV&SFLA_X^!:>[[O?WFKXB ?,N;J2?KKIIE,[[K"3.NNL(6J!^1>0
M:+6SWKV+M$GABLNN5+OIG<7D<TDH\5DL E3P4L$;VSGX@ @0@<P@0(5(9IHJ
M$X1BXOONN^^H;[6KFDY++VT6T)BLAH9JY1-:+M-G&P'RLVRW7RM0#\' ===?
MJYYX?+3JUFWU5J@RZ]@&!$2 2 5O&T#DJT2 "#0% N1G3=$,N23BBR^^4#C#
M]^MOOE9++[6T\2AE5Q1>HZ!HP;F[]]QUG_W(>U\N/^]+C&PI!(2?4<';4LUN
M*OO;;[\9?O.1YBMSS3F76GKI3D5'E*5%!.Z4/_[X8S5I\B<FG\Z=N^AC%V=+
M^WI).O*Y$D@8D18!*GBIX$W;5YB."!"!YD6 "I'F;1M21@2(0!@"Y&=A>#%U
M?1' V4I+=UY2+=EA2?7<LR_4MW"6EDD$1(!(!6\FFX]$$P$B8"% ?F:!P=NZ
M(G#6V6>HTTX?K&Z^:9C:>JMMZEHV"\LG L+/J.#-9_MFL5;D<UELM2:AF0I>
M*GB;I"N2#") !-J  !4B;0"/KQ(!(M!4")"?-55SD!@'@5=??46=<^X0M=UV
M?=1VV_9QGO(G$2A%0 2(5/"68L,8(D $LH4 ^5FVVBM/U)Y\RDEZI]Q'Z@I]
MO-!,,\V4IZJQ+@U"0/@9%;P-:@ 66X( ^5P))(Q(BP 5O%3PINTK3$<$B$#S
M(D"%2/.V#2DC D0@# 'RLS"\F)H($('F1D $B%3P-G<[D3HB0 3*(T!^5AXC
MIB "1" ;" @_HX(W&^U%*HD $4A @ I>*G@3N@<?$0$BD!$$J!#)2$.13")
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MY<)YYYUG=M#B'2A3H8##WPX[[!"]NL(**QA%!92&VVVW74&[B#/YXQTHE.V
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M\.W $P04FPA03B(>.W/M@!VTV/D%?C9APH3H$78T8@*+[]TVL BI*]RY8\P
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MUP&4']C5B]UOZ$N///*(6P1_ET&@&?F9?&.N@A=5D9T:"RZX8 $&7!)"O)3
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M%2+9;A%2WU8$]$Y:(Y309Y08P2PFQ6>>>::ZXHHKE-[)HX8-&];6(OA^DR)
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M;S-UHQ%(NUZ5=#!D\06LG:'DM8WYX_A:J-PP+A\??P1M(>O$N+Q]ZRKD+>>
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MI9'SSS\_;;[YYK-5C7S>08ZKLUJ1>79RX]D\:W#5)=!A@3*>"7@[W,BJ1H#
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MG__\ZN:;;QYQW?@A_GV,\M;O1E[@.QNF+V \F[ZA,Q @,!P"93R+__:T$"!
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MQJM3^3[6Y=^.>-?Y*JNLDI]6$>_JM<R>@/%L]FR=F0"!P0J4\4S .UAW5R-
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M+;=L8Y5FK,SE!J* =\9(G8A %GC'.]Z1XE'0'_WH1_/CKK',OH#Q;/:-78$
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M"!"H!02\N@$! @2F*2 0F2:@PPD0&!H!X]G0-(6"$" P P+E!J* =P8PG8(
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M;-XVO8H3Z*1 N8$HX.UD\ZH4@7DE8#R;5\VML@0Z+5#&,P%OIYM9Y0@0&)"
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MLEE5BL"\%2@W$ 6\\[8+J#B!S@@8SSK3E"I"8-X+E/%,P#OONP(  @1F0$#
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M1:",9P+>(F)-@ "!Y@("WN9VCB1 @$ 6$(CH" 0(=$7 >-:5EE0/ @1"H-Q
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M 0)=$3">=:4EU8, @1 H-Q %O/H# 0)M%S">M;T%E9\ @2)0QC,!;Q&Q)D"
M0',! 6]S.T<2($ @"PA$= 0"!+HB8#SK2DNJ!P$"(5!N( IX]0<"!-HN8#QK
M>PLJ/P$"1:",9P+>(F)-@ "!Y@("WN9VCB1 @$ 6$(CH" 0(=$7 >-:5EE0/
M @1"H-Q %/#J#P0(M%W >-;V%E1^ @2*0!G/!+Q%Q)H  0+-!02\S>T<28
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MY2= H B4\4S 6T2L"1 @T%Q P-O<SI$$"!#( @(1'8$ @:X(&,^ZTI+J08!
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M!-HN8#QK>PLJ/P$"1:",9P+>(F)-@ "!Y@("WN9VCB1 @$ 6$(CH" 0(=$7
M>-:5EE0/ @1"H-Q %/#J#P0(M%W >-;V%E1^ @2*0!G/!+Q%Q)H  0+-!02\
MS>T<28  @2P@$-$1"!#HBH#QK"LMJ1X$"(1 N8$HX-4?"!!HNX#QK.TMJ/P$
M"!2!,IX)>(N(-0$"!)H+"'B;VSF2  $"64 @HB,0(- 5 >-95UI2/0@0"(%R
M U' JS\0(-!V >-9VUM0^0D0* )E/!/P%A%K @0(-!<0\#:W<R0! @2R@$!$
M1R! H"L"QK.NM*1Z$" 0 N4&HH!7?R! H.T"QK.VMZ#R$R!0!,IX)N M(M8$
M"!!H+B#@;6[G2 ($"&0!@8B.0(! 5P2,9UUI2?4@0" $R@U$ :_^0(! VP6,
M9VUO0>4G0* (E/%,P%M$K D0(-!<0,#;W,Z1! @0R ("$1V! (&N"!C/NM*2
MZD& 0 B4&X@"7OV! (&V"QC/VMZ"RD^ 0!$HXYF MXA8$R! H+F @+>YG2,)
M$""0!00B.@(! ET1,)YUI275@P"!$"@W$ 6\^@,! FT7,)ZUO065GP"!(E#&
M,P%O$;$F0(! <P$!;W,[1Q(@0" +"$1T! ($NB)@/.M*2ZH' 0(A4&X@"GCU
M!P($VBY@/&M["RH_ 0)%H(QG MXB8DV  ('F @+>YG:.)$" 0!80B.@(! AT
M1<!XUI665 \"!$*@W$ 4\.H/! BT7<!XUO865'X"!(I &<\$O$7$F@ ! LT%
M!+S-[1Q)@ "!+" 0T1$($.B*@/&L*RVI'@0(A$"Y@2C@U1\($&B[@/&L[2VH
M_ 0(%($RG@EXBX@U 0($F@L(>)O;.9(  0)90""B(Q @T!4!XUE76E(]"! (
M@7(#4<"K/Q @T'8!XUG;6U#Y"1 H F4\$_ 6$6L"! @T%Q#P-K=S) $"!+*
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M+2+6! @0:"X@X&UNYT@"! AD 8&(CD" 0%<$C&==:4GU($ @!,H-1 &O_D"
M0-L%C&=M;T'E)T"@")3Q3,!;1*P)$"#07$# V]S.D00($,@" A$=@0"!K@@8
MS[K2DNI!@$ (E!N( E[]@0"!M@L8S]K>@LI/@$ 1*..9@+>(6!,@0*"Y@("W
MN9TC"1 @D 4$(CH" 0)=$3">=:4EU8, @1 H-Q %O/H# 0)M%S">M;T%E9\
M@2)0QC,!;Q&Q)D" 0',! 6]S.T<2($ @"PA$= 0"!+HB8#SK2DNJ!P$"(5!N
M( IX]0<"!-HN8#QK>PLJ/P$"1:",9P+>(F)-@ "!Y@("WN9VCB1 @$ 6$(CH
M" 0(=$7 >-:5EE0/ @1"H-Q %/#J#P0(M%W >-;V%E1^ @2*0!G/!+Q%Q)H
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M"!C/NM*2ZD& 0 B4&X@"7OV! (&V"QC/VMZ"RD^ 0!$HXYF MXA8$R! H+F
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MK_Y @$#;!8QG;6]!Y2= H B4\4S 6T2L"1 @T%Q P-O<SI$$"!#( @(1'8$
M@:X(&,^ZTI+J08! ")0;B )>_8$ @;8+&,_:WH+*3X! $2CCF8"WB%@3($"@
MN8" M[F=(PD0() %!"(Z @$"71$PGG6E)=6# ($0*#<0!;SZ P$";1<PGK6]
M!96? ($B4,8S 6\1L29 @$!S 0%O<SM'$B! ( L(1'0$ @2Z(F \ZTI+J@<!
M B%0;B *>/4' @3:+F \:WL+*C\! D6@C&<"WB)B38  @>8" M[F=HXD0(!
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MC&==:4GU($ @!,H-1 &O_D" 0-L%C&=M;T'E)T"@")3Q3,!;1*P)$"#07$#
MV]S.D00($,@" A$=@0"!K@@8S[K2DNI!@$ (E!N( E[]@0"!M@L8S]K>@LI/
M@$ 1*..9@+>(6!,@0*"Y@("WN9TC"1 @D 4$(CH" 0)=$3">=:4EU8, @1 H
M-Q %O/H# 0)M%S">M;T%E9\ @2)0QC,!;Q&Q)D" 0',! 6]S.T<2($ @"PA$
M= 0"!+HB8#SK2DNJ!P$"(5!N( IX]0<"!-HN8#QK>PLJ/P$"1:",9P+>(F)-
M@ "!Y@("WN9VCB1 @$ 6$(CH" 0(=$7 >-:5EE0/ @1"H-Q %/#J#P0(M%W
M>-;V%E1^ @2*0!G/!+Q%Q)H  0+-!02\S>T<28  @2P@$-$1"!#HBH#QK"LM
MJ1X$"(1 N8$HX-4?"!!HNX#QK.TMJ/P$"!2!,IX)>(N(-0$"!)H+"'B;VSF2
M  $"64 @HB,0(- 5 >-95UI2/0@0"(%R U' JS\0(-!V >-9VUM0^0D0* )E
M/!/P%A%K @0(-!<0\#:W<R0! @2R@$!$1R! H"L"QK.NM*1Z$" 0 N4&HH!7
M?R! H.T"QK.VMZ#R$R!0!,IX)N M(M8$"!!H+B#@;6[G2 ($"&0!@8B.0(!
M5P2,9UUI2?4@0" $R@U$ :_^0(! VP6,9VUO0>4G0* (E/%,P%M$K D0(-!<
M0,#;W,Z1! @0R ("$1V! (&N"!C/NM*2ZD& 0 B4&X@"7OV! (&V"QC/VMZ"
MRD^ 0!$HXYF MXA8$R! H+F @+>YG2,)$"! @  ! @0($"! @  ! @0($"!
M@  ! @0($" P4 $![T"Y78P  0($"! @0(   0($"! @0(   0($"! @0(
M 0+-!02\S>T<28   0($"! @0(   0($"! @0(   0($"! @0(  @8$*"'@'
MRNUB! @0($"   $"! @0($"   $"! @0($"   $"! @0:"X@X&UNYT@"! @0
M($"   $"! @0($"   $"! @0($"   $"! @,5$# .U!N%R- @  ! @0($"!
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MTDM6>_X"VVT@0(   0($"! @0(   0($"! @0(   0($"! @0(  @?\1&&C
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M O-)8" ![\]O."^=<?W/)^WZW)6>F9[YV*TFO;\="1 @0(   0($"! @0(
M 0($"! @0(   0($"! @,!\$9CW@?>"A!]*GZMF[=SUXSZ0]'['84ND=]2S>
MARWZL$D?8T<"! @0($"   $"! @0($"   $"! @0($"   $"! AT76#6 ]YS
M;[H@?>_:'T_9<8=5MDM/><QF4S[. 00($"! @  ! @0($"! @  ! @0($"!
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MM]]^>WK-:UZ3CSOZZ*/3:JNM-N(<_$9P^($  0($"! @0(   0($"! @0(
M 0($"! @0& &!02\,XC9E5/]_.<_3\]^]K-S=2+@?<$+7M"5JLU(/:Z__OJT
M\LHKYW/][G>_2YMNNNF(\_(;P>$' @0($"! @  ! @0($"! @  ! @0($"!
M@ "!&100\,X@IE/-#X&) M[YH:"6! @0($"   $"! @0($"   $"! @0($"
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M@'>//?9(7_SB%T<$O#'#^[;;;DN?^<QG4OB.7@2\HT7\3(   0($"! @0(
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M'A<]R(#W5:]Z5?KRE[^<*59===7TM[_]+7WD(Q_)OWQ0?,I:P%LDK D0($"
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M1O ]>AG++_996)^([\<*>*.=XSI++[UT%<;]RYUWWEG5[SW.WPMX^V5\)D"
M  $"! @0($"   $"! @0($"   $"! AT5Z 3CVBN [!4SS1-=6@:'WO+Y9=?
MGM9;;[W>S_%AN>66R^_J/?300],&&VS0^ZZ>B9F>\I2GI#K42X<<<DBJ9P+G
M[^K9O/G=O/'#T4<?W?O<.W"<#^41S5MMM55^'/1&&VV4][SAAAOR.>+QT/6,
MX73>>>>E+;?<,G\WF4<*QSMXXUV\<>R!!QZ8_]3A7S[^EEMN2=___O=S^>O
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M@'>L]ZT.5VF59I@%(DB/T#D>7=V__/SG/T_/?>YS\_MY8\;OZ!GA_?OZ3(
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M($"   $"! @0($"   $"! @0($"   $"! @4 0%OD; F0(   0($"! @0(
M 0($"! @0(   0($"! @0(# D L(>(>\@12/  $"! @0($"   $"! @0($"
M  $"! @0($"   $"14# 6R2L"1 @0(   0($"! @0(   0($"! @0(   0($
M"! @,.0" MXA;R#%(T"   $"! @0($"   $"! @0($"   $"! @0($" 0!&8
ME8#WNJ,/3?_\XV7E&M->+[GVAFGEMQPZ[?,X 0$"! @0($"   $"! @0($"
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M]LS"NLR=YU3MS.X-W><\I[M_V'=_3A]%@=,2\ 8UJGA5[Q[%PT:?"1 @0(
M 0($"! @0(   0($"! @0(   0($"! X'0*G+> =5;RJ=T_'M-LG 0($"! @
M0(   0($"! @0(   0($"! @0(   0)'4>"T!;QA_?I]ETUW?>%KCZ*;/A,@
M0(   0($"! @0(   0($"! @0(   0($"! @0.!_+G!: ][_^6CMD  ! @0(
M$"! @  ! @0($"! @  ! @0($"! @  ! D=80,![A"=/UPD0($"   $"! @0
M($"   $"! @0($"   $"! @0.%X" M[C-=]&2X   0($"! @0(   0($"! @
M0(   0($"! @0(# $180\![AR=-U @0($"! @  ! @0($"! @  ! @0($"!
M@  ! @2.EX" ]WC-M]$2($"   $"! @0($"   $"! @0($"   $"! @0('"$
M!02\1WCR=)T  0($"! @0(   0($"! @0(   0($"! @0(  @>,E(. ]7O-M
MM 0($"! @  ! @0($"! @  ! @0($"! @  ! @0('&$! >\1GCQ=)T"   $"
M! @0($"   $"! @0($"   $"! @0($#@> D(>(_7?!LM 0($"! @0(   0($
M"! @0(   0($"! @0(   0)'6$# >X0G3]<)$"! @  ! @0($"! @  ! @0(
M$"! @  ! @0($#A> @+>XS7?1DN   $"! @0($"   $"! @0($"   $"! @0
M($" P!$6$/ >X<G3=0($"! @0(   0($"! @0(   0($"! @0(   0($CI>
M@/=XS;?1$B! @  ! @0($"! @  ! @0($"! @  ! @0($"!PA 4$O$=X\G2=
M  $"! @0($"   $"! @0($"   $"! @0($"  ('C)2#@/5[S;;0$"! @0(
M 0($"! @0(   0($"! @0(   0($"!QA 0'O$9X\72= @  ! @0($"! @  !
M @0($"! @  ! @0($"! X'@)"'B/UWP;+0$"! @0($"   $"! @0($"   $"
M! @0($"   $"1UA P'N$)T_7"1 @0(   0($"! @0(   0($"! @0(   0($
M"! X7@("WN,UWT9+@  ! @0($"! @  ! @0($"! @  ! @0($"! @, 1%A#P
M'N')TW4"! @0($"   $"! @0($"   $"! @0($"   $"!(Z7@(#W>,VWT1(@
M0(   0($"! @0(   0($"! @0(   0($"! @<(0%!+Q'>/)TG0 ! @0($"!
M@  ! @0($"! @  ! @0($"! @ "!XR4@X#U>\VVT! @0($"   $"! @0($"
M  $"! @0($"   $"! @<80$![Q&>/%TG0(   0($"! @0(   0($"! @0(
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M8^Z3G_SD?)XUMYVW+1_='(_6M2#'<=ZN70/W!KQKXUAS/:S;Z+??! @0($"
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MCWK47/F;[;@1H'-]S''[VG0-;#_+\V!MWNO;FFO7XH.ZU2^-  $"! @0($"
M  $"! @0($"   $"! @<)X%3$O .P$+5_A1<M"1L%;@M3UH5;E6GA:W+D'%\
M;[QWP047S%5OX_6"ID*GJD5'0%#X-H*\ L4"HUH5B*,5UA5:]+VJ$0M$"V(+
MJ>I/RP O/S^^-WX7?K8$<V'.LE7U^9#_5-$5(!>LM(VJ@@O9>KU]C !MO_TM
M ]Y"VBH[1Z7=V->F@'<Y[E%MU_CJPYI!8RFD?L4K7G%B6>K#!+S+?;>=*CI'
MGPN[1@!58-D<[PWAQ[C&[TW!Z0AB1YC;9_,O>#KOO//F8'IMG%6&[VV;MMMG
M"C(+E*K:;<G=97O]ZU\_S^6F?BZ#K4*I3<?EWOFY[+++YL"T$'6T94@W7EO^
M7NM?%9AKQ\ZH\%T>ZXVU\S+3EKXN'*W"]-G/?O:)W7<C1NU%+WK1UO.VSRP]
MFO_ZU+%?^#]: 7H5V=T0L>W<&9]?_EYS:%^;QC#.K6U]6>YG_'UM/KNN=8QO
MNU8=-*A<ZV/7S8[YKEE5E8^V/'9.)N!M.]TL475TUX3&5%5R2^6W)'IM[1IX
MV'E?<^W</:C;W$$_"! @0(   0($"! @0(   0($"! @0(# ,1(XI0'OTK'*
MK\*<*B*KKBWXO?KJJ^=EA_<N5UK(UGO+<*]M%=P4T.P7\!96O>E-;YK#HY9+
MWMNJVBP@+GAJ'SVOLK"I;581V[+(>UMAY;O?_>YY&>F>/5M%8-67A9HCX"U8
MKIJX98[;9O\> 5;;V[:_9< [@NVQ=.KHRUK .Y:!SJ4@;<V@OH^*YA&.GVS
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M1N\5/'<<=^/!3='6KH&;]K$VCDW?V?O:8=SV?M>_"1 @0(   0($"! @0(
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M @0($"! @  ! @0($"! @  ! @0($""PTP("WIV>7H,C0(   0($"! @0(
M 0($"! @0(   0($"! @0&"7! 2\NS2;QD*   $"! @0($"   $"! @0($"
M  $"! @0($" P$X+"'AW>GH-C@ ! @0($"! @  ! @0($"! @  ! @0($"!
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M @0($"! 8)<$!+R[-)O&0H   0($"! @0(   0($"! @0(   0($"! @0(#
M3@L(>'=Z>@V.  $"! @0($"   $"! @0($"   $"! @0($"  (%=$A#P[M)L
M&@L! @0($"! @  ! @0($"! @  ! @0($"! @  ! CLM(.#=Z>DU. ($"! @
M0(   0($"! @0(   0($"! @0(   0($=DE P+M+LVDL! @0($"   $"! @0
M($"   $"! @0($"   $"! CLM(" =Z>GU^ ($"! @  ! @0($"! @  ! @0(
C$"! @  ! @0($-@E@?\'-HC^*#!V/$8     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
